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ABSTRACT 
NIH guidelines recommend treatment of moderate or severe childhood asthma with 
preventive anti-inflammatory medication (inhaled corticosteroids. cromolyn or nedocromil). 
The guidelines also emphasize providing patient education. 
The study objectives were a) to determine if the NIH guidelines for the treatment of 
childhood asthma were implemented by prescribing preventive medication. b) to determine 
if the NIH guidelines for the treatment of childhood asthma were implemented by providing 
patient education and c) to measure the influence of primary care physicians prescribing in 
accordance with the NIH guidelines on adverse clinical outcomes. Adverse clinical 
outcomes were measured by severe asthma exacerbations resulting in: hospital admissions. 
emergency department visits or a course of oral steroids from the primary care physicians. 
The data were collected from primary-care physicians in nine managed care plans in the 
northeastern USA. 311 children enrolled in Medicaid (aged 2-19 years) were identified as 
having a diagnosis and treatment for asthma during the period January through December 
1994. Detailed clinical and pharmacy data were extracted from medical records by nurse 
reviewers forthe period January 1993 through March 1995. 
The NIH guidelines for the use of preventive anti-inflammatory medication were 
implemented on at least one occasion for 61. l % of the children with moderate or severe 
asthma in this Medicaid population during 1994. Patient education was provided to 41.8% 
of the children. Cox regression analyses showed prescribing preventive medication for 
moderate to severe asthmatics in accordance with the NIH guidelines was associated with a 
reduced risk of receiving a course of oral steroids. 
( 
The findings of the present study suggest that many children with moderate or severe 
asthma were not prescribed preventive medication or provided education by primary care 
providers as recommended in the NIH guidelines. Inadequate implementation of the NIH 
guidelines for prescribing preventive medications was associated with adverse clinical 
outcomes. 
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PREFACE 
This dissertation is organized using the manuscript fo rmat. Part I consists of the three 
manuscripts that form the main body of the dissertation. Part 2 contains the appendices 
which provide the details requ ired by the Uni versity but are not usuall y presented in a 
published paper. 
Part I includes the following man uscripts: 
Study I: Medications prescribed to ast hmatic children: 
a historical cohort study of the implementation of NIH recommendations 
Study 2: Patient education prov ided to asthmatic children: 
a hi storical cohort study of the implementation of NIH recommendati ons 
Study 3: Divergence from NIH guidelines for pharmacologic therapy and 
ri sk of adverse outcomes in asthmatic children: a hi stori cal cohort study 
Part 2 includes the following appendices: 
Appendix A. Introduction and review of the problem 
Appendix B. Details of the methods 
Appendix C. Overview of major findings 
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PART 1 
Part l includes the following manuscripts: 
Study 1: Medications prescribed to asthmatic children: 
a historical cohort study of the implementation of NIH recommendations 
Study 2: Patient education provided to asthmatic children: 
a historical cohort study of the implementation of NIH recommendations 
Study 3 : Divergence from NIH guidelines for pharmacologic therapy and 
risk of adverse outcomes in asthmatic children: a historical cohort study 
Medications prescribed to asthmatic children : a historical cohort study of 
the implementation of NIH recommendations 
ABSTRACT 
Background: NIH guidelines recommend treatment of moderate or severe childhood 
asthma with preventive anti-inflammatory medication (inhaled corticosteroids. cromolyn or 
nedocromil). 
Objective: To determine if the NIH guidelines for the treatment of childhood asthma were 
implemented by examining the prevalence of prescribing preventive medication. We also 
examined clinical and demographic predictors of receiving preventive medication. 
Design: Non-concurrent cohort study. 
Setting: 9 managed care plans in the northeastern USA. 
Subjects: 311 children (aged 2 to 19 years) who were treated for asthma between January 
and December 1994. 
Main outcome: Prescribing preventive medication. 
Results: Preventive medications were prescribed at least once to 61.1 % and more than 
once to 27.0% of the children with moderate or severe asthma during 1994. Preventive 
medication was prescribed at least once to 27. l % of the children with mild asthma during 
1994. 
2 
Logistic regression analyses indicated that preventive medication was more likely to be 
prescribed for those with moderate or severe compared with mild asthma (aOR 5.34. 95% 
CI 3.22-8.83) and for older children. (age 5 to 19 years compared with 2 to 4 years. aOR 
2.11. 95% CI 1.19-3.72). Prescribing preventive medication was also associated with a 
prior emergency department visit (aOR 2.27, 95% CI 1.24-4.16), after adjusting for age. 
Conclusions: The NIH recommendations were implemented by prescribing preventive 
medication for 66.7% of the moderate or severe asthmatics over 4 years old during 1994. 
This study suggests there may be a need for interventions to increase the implementation of 
the NIH guidelines by primary care physicians and improve the treatment of childhood 
asthma. 
3 
INTRODUCTION 
In 1991 an Expert Panel prepared NIH guidelines for the diagnosis and management of 
asthma. ' The Expert Panel updated the recommendations in 1997 and continued to 
emphasize the role of inflammation in the pathogenesis of asthma.' The panel outlined an 
approach to asthma therapy that has four components : patient education, environmental 
control, comprehensive pharmacologic therapy and objective monitoring measures to 
monitor the severity of disease and course of therapy. 
Daily long term preventive anti-inflammatory medications (such as inhaled corticosteroids, 
cromolyn sodium or nedocrornil) are recommended for persistent asthma.2 Children 
consistently requiring symptomatic treatment more than twice a week (classified as 
moderate or severe asthmatics) should be given daily anti-inflammatory therapy. In 
addition, appropriate medications to manage acute asthma exacerbations (beta-agonists and 
oral corticosteroids) should also be prescribed. 
This study determines the extent to which the NIH guidelines for the treatment of childhood 
asthma were implemented by examining the prevalence of prescribing preventive 
medication by primary care physicians. In addition, this study identifies the demographic 
characteristics, clinical characteristics or events that are predictors of prescription of 
preventive medication to children. Evidence that guidelines influence patient care is needed 
because the effectiveness of guidelines in changing practice behaviors and improving health 
outcomes is widely questioned.3 4 5 
4 
METHODS 
Data source and study population 
The data analyzed were from a sample of3 I I children (aged 2 to 19 years) treated for 
asthma during 1994 in a Medicaid program in the northeastern USA. 
Pharmacy and clinical data were requested from nine managed care plans. Each plan was 
requested to identify all Medicaid members who were diagnosed and treated for asthma 
during 1994 (International Classification of Diseases, Ninth Revision, Clinical modification 
code ICD-9=493) and select a random sample of 50 children (aged 2 to 19 years in 1994) 
to study. The plans provided 388 medical records and 347 were eligible after verifying the 
patient's age on 1st January 1994 was between 2 to 19 years old (41 were less than 2 years 
old). 311 were eligible after confirming there was a visit with documentation of a 
prescription foran asthma medication during 1994(36out of347 did not have 
documentation of a visit during 1994). 
The data abstracted on asthma treatment provided by plan physicians between I st January 
1993 and 3 I st March 1995 were abstracted from the medical records. Medication data 
abstracted included all the asthma medications prescribed (product name, route, directions , 
days supply}, date prescribed and prescriber (primary care physician or other). The clinical 
data included the date of each physician visit, an assessment of the asthma severity at each 
visit, date of birth, gender, date of initial asthma diagnosis, date of latest theophylline level , 
date of latest influenza vaccination, and types of patient education provided at each visit 
(ability to use peak flow meter, ability to use inhaler, how to use inhaler, side effects of 
medication, avoidance of triggers, action plan for exacerbations, use of diaries, and goals 
of treatment). For each visit there was also a record of height, weight, blood pressure, a 
physical examination, medical history (symptoms and functional status), objective 
5 
measures of lung function (peak expiratory flow rates. home use of a peak flow meter. 
spirometry results) and referrals to specialists (dates, type of specialist. reason ). 
The clinical outcomes extracted from the medical records included asthma-related hospital 
admissions or emergency department visits (admission dates, discharge dates and reason 
for visit or admission ). A physician visit resulting in the prescription of a course of oral 
steroids was also considered as an outcome. 
Procedures 
A data collection instrument and abstracting instructions were provided to nurses who 
reviewed the members· medical records, and hospital or emergency department encounter 
files. For each physician visit the nurse reviewer recorded the pharmacy and clinical data 
requested, such as asthma severity , patient education and asthma medications prescribed. 
The nurse used the information in the medical records and the NIH guidelines to classify 
the asthma severity at each visit as mild, moderate or severe asthma. 
Statistical analyses 
Descriptive statistics were used to document the age, gender, asthma severity, medications 
prescribed, and clinical outcomes for the 311 children treated for asthma during 1994. 
On each date when asthma medications were prescribed these were coded as beta-agonists 
(oral or inhaled), preventive anti-inflammatory medications (inhaled corticosteroids, inhaled 
cromolyn or nedocromil) , oral theophylline or oral corticosteroids. The children were 
coded as receiving undertreatment at a visit where the disease severity was recorded to be 
moderate or severe and no preventive medications were prescribed. The maximum asthma 
severity recorded in 1994 was used to code the children as mild, moderate or severe 
asthmatics. 
6 
Preventive medication and undertreatment ever being prescribed during the study were used 
as dichotomous dependent variables in bivariate analyses (Mantel-Hanszel chi square tests) 
and in multivariate logistic regression. Independent variables in these models included age, 
gender, asthma severity, prescribing a course of oral steroids at the same visit or a prior 
visit, prior admission to hospital or a prior emergency department visit. Multivariate 
adjusted odds ratio, 95% Wald confidence interval (Cl), Wald chi-square statistic and the 
p-value for a two sided significance test were calculated for each independent variable. 
Age was coded as a dichotomous variable (2 to 4 years and 5 to 19 years) after establishing 
that the associations were not linear for each dependent variable. Asthma severity was 
coded categorically as mild ( I), moderate (2), or severe (3). In addition, for the 
multivariate model for prediction of prescribing preventive medication, asthma severity was 
coded as a dichotomous variable mild (0) and moderate or severe asthma (I). 
7 
RESULTS 
Descriprive and bivaricue analyses 
Frequency distributions of demographic characteristics, a~thma severity, medications 
prescribed, emergency department visits and hospitalizations are summarized in Tables 1-2. 
Moderate or severe asthma was experienced by 49.4% ( 126) of the children, 20.9% (65) 
were prescribed oral steroids. 18.7% (58) made an emergency department visit and 6.8% 
(2 1) were admitted to a hospital. During 1994. amongst the children with moderate or 
severe asthma, 27.0% (2 l) experienced severe asthma exacerbations. 44.4% (56) were 
prescribed oral steroids, 28% (35) made an emergency department visit and 11.9% ( 15) 
were admitted to a hospital. 
During 1994, the overall percentages of children prescribed asthma medications on at least 
one occasion were as follows: theophylline 4.8% ( 15), an inhaled steroid 17.7% (55), 
cromolyn or nedocromil 27.3% (83) and a beta-agonist 86.5% (269). 
Preventive medication (cromolyn, nedocromil or inhaled steroid) was prescribed on at least 
one occasion to 61. l % (77) and more than once to 27.0% (34) of the children with 
moderate or severe asthma. Preventive medication was prescribed on at least one occasion 
during 1994 to 27. l % (35) of the children with mild , 60.9% (56) with moderate and 
61.8% (21) with severe asthma (Table I). The results from the bivariate analyses showed 
that children were more likely to be prescribed preventive medication if they were aged 5 to 
19 years, male, or experienced moderate or severe asthma exacerbations. The results of 
this study indicated that the NIH guidelines for the use of preventive medications were 
implemented on at least one occasion for 66.7% of the children aged 5 to 19 years old with 
moderate or severe asthma during 1994. 
8 
A course of oral steroids at the same or prior visit or a prior emergency department visit 
were significantly associated with a subsequent prescription of preventive medication , but a 
prior hospital admission was not significantly associated with preventive medications 
subsequently being prescribed. 
65.9% (83) of the children with moderate or severe asthma were undertreated on at least 
one visit when other asthma medications were prescribed (Table 2). 38.9% (49) of the 
children with moderate or severe asthma were undertreated on 50% or more visits when 
other asthma medications were prescribed. A course of oral steroids was associated with 
an increased risk of undertreatment either at the same visit or subsequent visits. A prior 
emergency department visit was significantly associated with a reduced risk of 
undertreatment at subsequent visits, but a prior hospital admission was not significantly 
associated with undertreatment at subsequent visits . 
Mulrivariareanalyses 
Multivariate odds ratios are presented in Table 3 forthe independent associations between 
asthma severity, an oral steroid course and a prior emergency department visit and 
prescribing preventive medication , after adjusting for age. The children were significantly 
more likely to be prescribed preventive medication if they had moderate or severe 
compared to mild asthma exacerbations (aOR 5.34, 95% Cl 3.22-8.83) and were age 5 to 
19 years compared to 2 to 4 years old (aOR 2.11, 95% CI 1. 19-3 .72) . 
The independent associations between prescribing a course of oral steroids or a prior 
emergency department visit and subsequently prescribing preventive medications were also 
evaluated (without adjusting for asthma severity due to multicollinearity) (Table3). A 
course of oral steroids being prescribed at the same or prior visit (aOR 2.79, 95% CI l.57-
4.93) or a prior emergency department visit (aOR 2.27, 95% CI 1.24-4. 16) was associated 
9 
with prescribing preventive medication, after adjusting for age (Table 3). Gender was not 
significantly associated with preventive medication once age and asthma severity were 
included in the model. 
Multivariate odds ratios for the association between undertreatment of children with 
moderate or severe asthma and age, asthma severity, an oral steroid course, a prior 
emergency department visit or a prior hospital admission are presented in Table 4. 
Moderate compared to severe asthma was not a significant predictor of undertreatment 
(Table 4). A prior emergency department visit significantly reduced the risk of subsequent 
undertreatment by the primary care physician (aOR 0.24, 95% CI 0.10-0.60) but a course 
of oral steroids was associated with an increased risk (aOR 2.23. 95%CI 1.01-4.89) of 
undertreatment at the same visit or subsequent visits, after adjusting for age. Age 5 to 19 
years compared to 2 to 4 years was associated with less risk of undertreatment on 50% or 
more of the visits (aOR 0.44, 95% CI 0. I9- I .02), after adjusting for prior hospitalization, 
a prior emergency department visit and an oral steroid course. 
10 
DISCUSSION 
Asthma is the most common chronic illness in children and has been studied frequently as 
an indicator of the adequacy and appropriateness of ambulatory care. " 7 8 The impact of 
asthma on the health of children experiencing moderate or severe asthma in this study was 
reOected in the number admitted to a hospital ( 11.9%) or attending the emergency 
department (27.8%) during 1994. 
The results of this study suggest that the NIH guidelines for the use of preventive 
medications were implemented on at least one occasion for 66.7% of the children aged 5 to 
19 years old with moderate or severe asthma during 1994, in thi s Medicaid population. 
However, amongst children with moderate or severe asthma only 27.0% had more than 
one prescription for preventive medication documented in the medical records during 1994. 
Amongst the children with moderate or severe asthma, 38.9% were undertreated on 50% or 
more physician visits when other asthma medications were prescribed, and 65.9% were 
undertreated on at least one occasion. Thus, although the majority of patients with 
moderate or severe asthma were prescribed preventive medication at least once during 
1994, regular prescribing of preventive medication was not evident. The pattern of 
prescribing in this study is not consistent with full implementation of the NIH guidelines, 
which support regularly prescribing preventive anti-inflammatory medication to children 
with moderate or severe asthma. 
The NIH guidelines recommend anti-inOammatory medications but indicate that 
theophylline can be prescribed for childhood asthma. Theophylline has a narrow 
therapeutic index. For a child over 5 years old who needs maintenance medication, an 
inhaled steroid or cromolyn is considered the simplest and safest regimen.9 Slow-release 
theophylline does off er an alternative to inhaled corticosteroids when a patient complies 
poorly with a maintenance regimen of inhaled steroids or cromolyn and is judged more 
11 
likely to adhere to an oral regimen. In this study the prevalence of prescribing theophylline 
was very low (4.8% ), and cannot therefore account for the apparent undertreatment of 
moderate or severe asthmatics with anti -inflammatory products. 
The low overall prevalence of prescribing of preventive medications (cromolyn 27.3% and 
inhaled steroids 17.7%) and theophylline (4.8%) are comparable with those recorded in 
other studies of children in different health care settings. 10 11 Friday et al 9 studied children 
treated for asthma in the emergency department and calculated the percentages of children 
prescribed asthma medications before the visit were: cromolyn (35%), inhaled steroids 
(22%) and theophylline (6%). Donahue et al 10 analyzed the percentage of prescriptions for 
privately insured children and found a similar trend: 16% forcromolyn, 11 % inhaled 
steroids and 6% theophylline. 
The results from three recent studies of children with moderate or severe asthma have also 
suggested that the NIH guidelines recommending the use of preventive medication have not 
been fully implemented. Eggieston at al "collected questionnaires completed by the 
families of 166 asthmatic children requiring an emergency room visit in the past six 
months, and found less than 50% were receiving preventive medication. Lieu et al 13 
studied 508 children hospitalized or attending the emergency department as a result of 
severe asthma and 990 asthmatic controls. The study reviewed the medications prescribed 
to the children attending a physician within 30 days before either the hospital admission or 
emergency department visit and reported up to 49% were prescribed cromolyn or inhaled 
steroids. Homer et al 6 found that at most 33% of the children hospitalized for asthma had 
received cromolyn or inhaled steroids before admission. 
Low rates of repeat prescriptions for preventive medications were also obtained in other 
studies, including both adults and children. A study of moderate or severe asthmatics 14 
12 
(adults and chi ldren over7 years old), showed 63% were dispensed preventive medications 
(but only 32% were receiving preventive medications regularly). Another study' 5 also 
suggested less than 54% of the patients (adults and children over 12 years) prescribed anti -
inflammatory medications were refilling tbe medications regularly. A study of British 
children indicated'" very few (less than 15%) were dispensed preventive medications 
regularly. 
Inadequate attendance for primary care physician follow up visits were shown by a study 
in asthmatic children in the Medicaid program in Massachusetts 17 and similarly less 
continuous treatment 18 has been noted for asthmatic adults from lower socioeconomic 
groups. Focus groups of urban minority asthmatic children in New York 19 showed many 
parents and children had very modest expectations of symptom control. Asthma was 
viewed by the families as ''episodic" increasing their empbasis on symptomatic treatment 
rather than seeing the need for preventive visits. In our study, lack of continuity of care 
cannot completely explain the results because 38.9% of the children with moderate or 
severe asthma attended the primary care physician more than once and were not prescribed 
preventive medications. 
We examined five factors associated with prescribing preventive medication, including age , 
asthma severity, a prior emergency department visit or hospital admission or prescribing a 
course of oral steroids at the same or prior physician visit. The multivariate and bivariate 
analyses suggested that physicians were more likely to prescribe preventive medication for 
children aged 5 to 19 years old than younger children with moderate or severe asthma. 
These results were consistent with implementation of the NTH guidelines. Children 
younger than 5 years of age are recommended to be given courses of oral steroids for 
chronic severe asthma because they may be unable to use inhalers effectively.1 Children 
13 
with moderate asthma were at a similar risk to children with severe asthma for 
undertreatment, after adjusting for age. 
The physicians prescribed preventive medications to the children experiencing acute asthma 
exacerbations as indicated by an increased association between an emergency department 
visit or a course of oral steroids and subsequent prescribing of preventive medication, after 
adjusting for age. Amongst the children with moderate or severe asthma, there was also a 
reduced risk of subsequent undertreatment among those with an emergency department 
visit, after adjusting for age. However, in contrast, a course of oral steroids, after 
adjusting for age, was associated with undertreatment either at the same or subsequent 
physician visits. Thus, the prescribing was not consistent with implementing the NIH 
guidelines for children attending with moderate or severe asthma: even aftertaking into 
account the difficulty of treating children under 5 years old with inhaled medications. 
The study design did not include a sample size large enough to allow comparisons between 
the different managed care plans or profile the prescribing practices of individual 
prescribers. Asthma specialists have been shown to be more likely to prescribe preventive 
medications than primary care physicians20 21 and access to or co-ordination of care by 
specialists" 23 may have facilitated implementation of the NIH guidelines by some plans. 
It was not possible to compare the results from this Medicaid group with other patients 
attending these plans. Access to Medicaid for children is generally related to low family 
income, therefore this study selected children with a low socioeconomic status. The 
infonnation collected from this Medicaid asthmatic population may not be generalizable to 
other children. There could be differences in prescribing practices or attendance at the 
physician office for preventive care visits by Medicaid patients. 
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In the present study medications were free for the patients; thus there was no cost incentive 
for patients to avoid having prescriptions dispensed for preventive medications. The 
managed care plans guarantee access for these Medicaid patients but there are many 
differences between poor minority families and health care providers that may influence 
prescribing practices for example language, cultural barriers, or literacy levels. 19 
Hospitalization was not found to be associated with subsequent prescribing of preventive 
medications. However, the frequency of hospitalization showed a seasonal variation. This 
variation, in combination with the small sample size and the variability of asthma severity , 
may have limited the ability of this study to detect an association. 
An unusual aspect of this study was the collection of clinical data from primary care 
physician medical records. The asthma diagnoses were confirmed from the medical records 
and therefore the study did not have to rely solely on the !CD 9 coding for the diagnosis. 
Using the medical records also allowed the classification of children as mild, moderate or 
severe asthmatics at each physician visit when an asthma medication was prescribed. The 
maximum severity recorded during 1994 was used to code the children as mild, moderate 
or severe asthmatics for the entire study period. The analyses were then able to address 
confounding by asthma severity. Most previous studies focused on severe asthmatics or 
did not use the NIH guidelines to assign a clinical assessment of asthma severity. A 
limitation of this study was that the information about medications prescribed was also 
collected from the medical records rather than a separate medication claims database; 
consequently, not all the prescriptions may have been dispensed or refills may not have 
been documented. 
There are many challenges to moving patients away from episodic attendance at the primary 
care physician's office or emergency department for crisis orientated care and provision of 
15 
fragmented care for asthma exacerbations."" The lack of regular prescribing of 
preventive medications for some children in our study may show a need for more patient 
education, provider training, and alternative disease management approaches to introduce 
asthma prevention strategies.26 27 28 
Studies of the impact of the NIH guidelines on the emergency department management of 
childhood asthma have suggested that implementation of the guidelines may be limited.29 30 
Lantneret al 29 surveyed physicians at academic medical centers with a pediatric residency 
program and found that at most half of those surveyed believed their emergency 
management of asthma was influenced by the NIH guidelines. Crain et al 30 surveyed 
physicians based at a sample of children· s emergency departments and found that 45.5% 
had heard of the guidelines and 24% had read them. Crain et al also reported under-use of 
steroids in the emergency departments and a wide variation in practices. 
Preventive medication was prescribed for 66.7% of the moderate or severe asthmatics over 
4 years old, which indicates there could be a substantial improvement in the management of 
childhood asthma by primary care physicians. Our study suggests that for some children 
prescribing of preventive anti -inflammatory medications was subsequent to an emergency 
department visit and that the NlH recommendations were not always routinely implemented 
by primary care providers for children with moderate or severe asthma. This study 
supports the need for interventions to increase implementation of the NIH guidelines by 
primary care physicians and improve the treatment of childhood asthma. 
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Table l Descriptive statistics and bivariate relationships between 
demographic characteristics, asthma severity or prior clinical events and 
prescribing of preventive medication, (n=Jll) 
Characteristics Total Preventive medication 
prescribed 
n % n % 
Total 311 121 38.9 
Age (years) 2-4 92 29.6 27 29.4 .03 
5-19 219 70.4 94 42.9 
Gender Female 146 47.3 47 32.2 .03 
Male 163 52.8 72 44.2 
Asthma severity 
Mild 129 50.6 35 27.I .00 
Moderate 92 36. 1 56 60.9 
Severe 34 13.3 21 61.8 
Oral steroid course 0 246 79.1 84 34.2 .00 
>=I 65 20.9 37 56.9 
Emergency visit 0 253 81.4 88 34.8 .03 
>=I 58 18.7 29 50.0 
Hospital admission 0 290 93.3 111 38.3 .65 
>=I 21 6.8 7 33 .3 
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Table 2 Descriptive statistics and bivariate relationships between demographic characteristics, 
asthma severity or prior clinical events and prescribing of preventive medication or 
undertreatment for children with moderate or severe asthma, (n=126) 
Charnctcri stics Total Preventive mc<lic;.1tion Um.Jcrtre<.1tmcnl Un<lcrtrcatmcnt 50% 
prcscri bell of \•isi ts 
n % 
" 
% 11 'ii n % 
Total 126 77 6 1.1 83 65.9 49 3K.9 
Age (years) 2-4 39 31.0 19 48.7 .06 28 71.8 .35 18 46.2 .27 
5- 19 87 69. I 58 66.7 55 63.2 31 35.6 
Gender Female 54 43.2 29 53.7 . 16 40 74. 1 .08 22 40.7 .76 
<O 
Male 71 56.8 47 66.2 42 59.2 27 38.0 
Severity Moderate 92 73 .0 56 60.9 .93 60 65.2 .80 35 38.0 .75 
Severe 34 27.0 21 61.8 23 67.7 14 41.2 
Oral steroid () 70 55.6 43 61.4 .94 40 57.I .02 25 35.7 .3 1 
course >= I 56 44.4 34 60.7 43 76.8 25 44.6 
Emergency visit 0 9 1 72.2 50 55.0 .28 61 67.0 .00 40 44.0 .06 
>= I 35 27.8 23 65.7 13 37.1 9 25.7 
Hospital 0 111 88. I 68 61.3 . 12 70 63.1 .09 41 36.9 .79 
admission >=I 15 I 1.9 6 40.0 6 40.0 5 33.3 
Table 3 Multivariate adjusted Odds Ratios and 95% confidence intervals 
(Cl) for predictors of receiving a prescription for preventive medication, 
(n=3 ll ) 
Characteristics Preventive medication prescribed 
aOR Cl 
Model/: 
Moderate or severe 5.34 .00 3.22-8.83 
compared to mild asthma 
Age >=5 years 2.11 .01 1.19-3 .72 
Mode/2: 
Prior oral steroid courses 2.79 .00 1.57-4.93 
compared with none 
Age >=5 years 2.02 .0 1 1.18-3.47 
Mode/3: 
Prior emergency department visits 2.27 .01 1.24-4.16 
compared with none 
Age >=5 years 2. 13 .01 1.22-3.70 
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Table 4 Multivariate adjusted Odds Ratios and 95 % confidence intervals 
(Cl) for predictors of undertreatment of children with moderate or severe 
asthma, (n=l26) 
Characteristics Undertreatment Undertreatment >=50% of visits 
aOR p Cl a OR p Cl 
Model I: 
Prior emergency visits 0.24 .00 0.10-0.60 0.30 .02 0.11 -0.79 
compared with none 
Prior hospital admissions 0.52 .29 0.15-1.75 0.79 .72 0.22-2.80 
compared with none 
Prior oral steroid courses 2.23 .05 1.01 -4.89 2.00 .08 0.91 -4.38 
compared with none 
Age >=5 years 0.74 .48 0.33- 1.70 0.44 .05 0.19-1.02 
Mode/2: 
Severe compared to 1.14 .76 0.49-2.65 1.12 .79 0.50-2.50 
moderate asthma 
Age >=5 years 0.67 .34 0.29- 1.53 0.67 .31 0.31 - 1.45 
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Patient education provided to asthmatic children a historical cohort study 
of the implementation of NIH recommendations 
ABSTRACT 
Background: NIH guidelines for the treatment of childhood asthma emphasize the 
importance of educating the patient and their famil y about avoiding triggers and providing 
information to support self-management of asthma therapy. 
Objective: To determine if the NIH guidelines for the treatment of childhood asthma were 
implemented by examining the prevalence of patient education provision by primary care 
physicians. We also examined clinical and demographic predictors of providing patient 
education. 
Design: Non-concurrent cohort study. 
Setting: 9 managed care plans in the northeastern USA. 
Subjects: 311 children (aged 2 to 19 years) who were treated for asthma between January 
and December 1994. 
Main outcomes: Patient education on the potential benefits from avoidance of 
environmental triggers. Provision ofa written action plan forthe treatment of acute 
exacerbations, explaining the goals of treatment and checking the ability to use an inhaler 
appropriately. 
Results: Patient education was provided at least once to41.8% of the children during 
1994. Logistic regression analyses indicated that two predictors of providing information 
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about avoidance of triggers were severe compared 10 mild or moderate asthma (aOR 3.61. 
95% CI 1.69-7.72) and being prescribed inhaled anti-inilammatory medications (aOR 
2.38. 95% CI 1.37-4.12), after adjusting for age. Inhaled an1i-inilamma1ory medications 
were prescribed for 61.1 % of !he children with moderate or severe asthma. and 27. I% of 
the children with mild asthma. 
Conclusions: The NIH recommendations to provide patient education were not 
implemented for at least half of the children during 1994. In addition. less than half of the 
children prescribed preventive medications or a course of oral steroids were also provided 
i nfonnation about avoidance of triggers. We conclude therefore that the I imited 
implementation of the NIH recommendations by primary care physicians in our study has 
substantially reduced the impact of the NIH guidelines on the management of poorly 
controll ed childhood asthma. 
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INTRODUCTION 
In 1991 an Expert Panel prepared NIH guidelines for the diagnosis and management of 
asthma.' The Expert Panel updated the recommendations in 1997 and continued to 
emphasize the role of inflammation in the pathogenesis of asthma.' The expert panel 
outlined an approach to asthma therapy that has four components : patient education, 
environmental control. comprehensive pharmacologic therapy and objective monitoring 
measures to monitor the severity of disease and course of therapy. 
The guidelines emphasize the importance of patient education in the management of asthma 
and the potential benefits from environmental control. The guidelines specifically 
recommend provision of action plans, information on avoidance of triggers, goals of 
treatment and ability to use an inhaler, use of diaries and side effects of medications. 
A written action plan to guide patient self-management is especially important for patients 
with moderate or severe persistent asthma and patients with a history of severe 
exacerbations. Asthma severity is highly variable and may change over time so assessment 
is recommended at least biannually. Routine assessment allows the physician to check that 
treatment goals are being met and that the patient is on appropriate pharmacotherapy with 
up to date self management and action plans. The ability to use the inhalers correctly 
should also be checked to ensure maximum benefit from the medication prescribed, 
especially if asthma control is not achieved. 
Exposure of an asthmatic patient to inhalant allergens to which the patient is sensitive 
increases airway inflammation and symptoms. Substantially reducing such exposure will 
result in significantly reduced inflammation, symptoms and need for medication. The NIH 
guidelines recommend that patients with asthma at all levels of severity receive education 
about the importance of minimizing exposure to inhalant triggers. The counseling should 
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include how to control and avoid exposure to known allergens, cigarette smoke and to 
make reasonable attempts to reduce exposure to respiratory viruses. 
This study determines the extent to which the NlH recommendations have been 
implemented by the primary care physicians for children with asthma in a randoml y 
selected population of Medicaid patients enrolled in managed care plans. The study 
summarizes provision of patient education and information about environmental control. In 
addition, the study identifies demographic characteristics, clinical characteristics or events 
that are predictors of primary care physicians providing patient education to children. 
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METHODS 
Data source and study population 
The data analyzed were from a sample of 311 children (aged 2 to 19 years) treated for 
asthma during 1994 in a Medicaid program in the northeastern USA. 
Pharmacy and clinical data were requested from nine managed care plans. Each plan was 
requested to identify all Medicaid members who were diagnosed and treated for asthma 
during 1994 (International Classification of Diseases, Ninth Revision, Clinical modification 
code ICD-9--493) and select a random sample of 50 children (aged 2 to 19 years in 1994) 
to study. The plans provided 388 medical records and 347 were eligible after verifying the 
patient's age on !st January 1994 was between 2 to 19 years old (41 were less than 2 years 
old). 3 l l were eligible after confirming there was a visit with documentation of a 
prescription for an asthma medication during 1994 (36 out of 347 did not have 
documentation of a visit during 1994). 
The data abstracted on asthma treatment provided by plan physicians between I st January 
1993 and 31st March 1995 were abstracted from the medical records. Medication data 
abstracted included all the asthma medications prescribed (product name, route, directions, 
days supply), date prescribed and prescriber (primary care physician or other). The clinical 
data included the date of each physician visit, an assessment of the asthma severity at each 
visit, date of birth, gender, date of initial asthma diagnosis, date of latest theophylline level, 
date of latest influenza vaccination, and types of patient education provided at each visit 
(ability to use peak flow meter, ability to use inhaler, how to use inhaler, side effects of 
medication, avoidance of triggers, action plan for exacerbations, use of diaries, and goals 
of treatment). For each visit there was also a record of height. weight, blood pressure, a 
physical examination, medical history (symptoms and functional status), objective 
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measures of lung function (peak expiratory flow rates. home use of a peak flow meter. 
spirometry results) and referrals to specialists (dates. type of speciali st, reason). 
Cl inical outcomes extracted from the medical records included asthma-related hospital 
admissions or emergency department visits (admission dates, discharge dates and reason 
for visit or admission). A physician visit resulting in the prescription of a course of oral 
steroids was also considered an outcome. 
Procedures 
A data collection instrument and abstracting instructions were provided to nurses who 
reviewed the members ' medical records, and hospital or emergency department encounter 
files. For each physician visit the nurse reviewer recorded the pharmacy and clinical data 
requested , such as asthma severity, type of patient education provided and asthma 
medications prescribed. The nurse used the information in the medical records and the 
NlH guidelines to classify the asthma severity at each visit as mild , moderate or severe 
asthma. If patient education was provided this was classified by the nurse reviewer in 
accordance with the recommendations in the NIH guidelines as providing an action plan for 
exacerbations, information on avoidance of triggers, goals of treatment and ability to use 
inhaler, medication side effects or use of diaries to record asthma exacerbations. 
Statistical analyses 
Descriptive statistics were used to document the age, gender, asthma severity. medications 
prescribed, clinical outcomes and the type of patient education provided for the 3 I I 
children treated for asthma during 1994. 
On each date when patient education was provided the four types of information were 
coded as provision of an action plan. information on avoidance of triggers, goals of 
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treatment and ability to use the inhaler. On each date when asthma medications were 
prescribed these were coded as beta-agonists (oral or inhaled) , preventive anti-
inflammatory medications (inhaled corticosteroids, inhaled cromolyn or nedocromil), oral 
theophylline or oral corticosteroids. 
Each type of education was used as dichotomous dependent variables in bivariate analyses 
(Mantel-Haenszel chi square tests) and in multivariate logistic regression models. 
Independent variables in these models included age, gender, asthma severity, prescribing 
preventive medication or a course of oral steroids at the same visit or a prior visit, prior 
admission to hospital or a prior emergency department visit. Multivariate adjusted odds 
ratio, 95% Wald confidence interval (Cl), Wald chi-square statistic and the p-value for a 
two sided significance test were calculated for each independent variable. The Bonferroni 
correction was used to calculate the appropriate significance level forthe p-values 
(p=<O.O 125). 
Age was coded as a dichotomous variable (2 to 4 years and 5 to 19 years) after establishing 
that the associations were not linear for each dependent variable. The maximum asthma 
severity recorded in 1994 was used to code the children as mild, moderate or severe 
asthmatics. For the multivariate analyses, the categories of asthma severity were collapsed, 
as appropriate, according to the associations found for each type of education. 
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RESULTS 
Descriptive and bivariareana/vses 
The rel ationships between provision of patient education and demographic characteri stics, 
asthma severity, medications prescribed, emergency department visits and hospitalizations 
are summarized in Tables 1-2. The Bonferroni correction was used to calculate the 
appropriate significance level for the p-values (p=<O.O 125). 
Patient education was documented for less than 50% of the children during 1994, 
regardless of the type of education. Specifically, action plans were provided on at least one 
occasion to 41 .8% ( 130) of the children during 1994. Information on the importance of 
avoiding triggers was provided to 24.4% (76) of the children. Limited patient education 
was provided to support self-management of asthma by using the medications prescribed 
appropriately; 13.5% (42) of the children received information on the goals of the treatment 
and 15.8% (49) had their ability to use the inhaler checked. 
Applying the criteria in NIH guidelines for asthma severity classified 50.6% ( 129) as mild 
asthmatics, 36. I% (92) experienced at least one moderate and 13.3% (34) at least one 
severe asthma exacerbation during 1994. Action plans were provided to 76.5% (26) of the 
children with severe asthma, 55.4% (51) with moderate asthma and 40.3% (52) with mild 
asthma. Information on avoidance of tri ggers was provided to 52.9% ( 18) of the children 
with severe asthma, 29.4% (27) with moderate asthma and 233% (30) with mild asthma. 
Bivariate analyses showed that children with moderate or severe asthma were more 
frequently provided an action plan for exacerbations, and information on avoidance of 
triggers or goals of treatment. 
Fewer than 25% of the children with moderate or severe asthma were documented in the 
medical records as being provided either: information on the goals of treatment or having 
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the ability to use the inhaler correctly confirmed. Fewer than 10% of children with 
moderate or severe asthma were provided information about medication side effects or used 
diaries. However, children prescribed a course of oral steroids were significantly more 
likely to be provided two types of patient education at the same or subsequent visits : 
information on avoidance of triggers (p-value =0.003) or a review of the treatment goals 
(p-value=0.01). 
Prescribing preventive medications was associated with providing three types of patient 
education. Preventive anti-inflammatory medication (inhaled corticosteroids, cromolyn or 
nedocromil) were prescribed by the primary care provider for 38.9% ( 121) of the children. 
The children prescribed preventive medication , were significantly more frequently provided 
three types of patient education : goals of treatment (p-value=0.001 ), action plan (p-
value=0.001), and avoidance of triggers (p-value=0.001). Prescribing preventive 
medication was not significantly associated with confirmation of the ability to use an 
inhaler. 
Adverse clinical events were not associated with subsequent provision of patient education 
by the primary care providers. Bivariate analyses did not show either emergency 
department visits or hospitalization to be significantly associated with subsequent provision 
of patient education. 
Multivariate analyses 
Multivariate odds ratios for the association between receiving four types of patient 
education and asthma severity, preventive medication, and age are presented as Model 1 
(Table 3). Multivariate odds ratios for the independent associations between an oral steroid 
course (Model 2), or an emergency department visit (Model 3) and the four types of patient 
education provided are presented in Table 3. The associations between hospitalizations and 
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provision of patient education were not estimated using multivariate analyses because of the 
small number of children admitted to hospital. The Bonferroni correction was used to 
calculate the appropriate significance level for the p-values (p=<0.0125). 
Multivariate analyses showed that asthma severity was significantly associated with the 
provision of three types of patient education: an action plan, information on avoidance of 
triggers and a review of treatment goals (after adjusting for age and prescribing preventive 
medication) (Table 3). The adjusted odds ratios for an action plan for exacerbations were 
as follows: moderate compared to mild asthma aOR 1.85 (95% CI 1.25-2.75), and severe 
compared to mild asthma aOR 3.43 (95% CI 2.32-5.09). The adjusted odds ratio for 
provision of information on avoidance of triggers to children with severe asthma compared 
to mild or moderate asthma was aOR 3.61 (95% CI 1.69-7 .72). The adjusted odds ratio for 
a review of the treatment goals for moderate or severe compared to mild asthma was aOR 
3.12 (95% CI 1.45-6.72). 
Associations between prescribing preventive medications and providing patient education 
are presented in Table3. Children prescribed preventive medication were significantly 
more likely to receive two types of patient education at subsequent visits (after adjusting for 
age and asthma severity) : avoidance of triggers (aOR 2.38, 95% CJ 1.37-4.12), and a 
review of the treatment goals (aOR 3.14, 95% CI 1.46-6.75) but not ability to use an 
inhaler. Children prescribed a course of oral steroids were also significantly more likely to 
be provided two types of patient education at the same or subsequent visits (after adjusting 
for age): avoidance of triggers (aOR 2.62, 95% Cl 1.43-4.77) and a review of the 
treatment goals (aOR 2.63, 95% Cl 1.29-5.36). 
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Emergency department visits were not associated with the subsequent provision of patient 
education by the primary care providers. A prior emergency department visit was not a 
significant predictors (after adjusting for age) for primary care providers subsequently 
providing an action plan (aOR 0.79, 95% CI 0.42- 1.49), information about avoidance of 
triggers ( aOR 0.84. 95% CI 0.39- 1.80), a review of treatment goals (aOR 2.49, 95%CI 
1.11-5.55), or confirming the ability to use an inhaler (aOR 1.21 , 95% CI 0.54-2.74). 
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DISCUSSION 
The NIH guidelines recommend that all asthmatic children receive education about asthma 
and avoidance of triggers. However, provision of patient education was not documented in 
the medical records for the majority of children in our study. Action plans for severe 
exacerbations were the most frequent form of patient education provided and were given to 
41.8% of the children . Action plans were provided to the majority of children with 
moderate (55.4%) or severe asthma (76.5% ). Multi variate analyses showed that asthma 
severity was significantly associated with provision of three types of patient education. 
However, fewer than 25% of the children with moderate or severe asthma were 
documented in the medical records as being provided either information on the goals of 
treatment or having the ability to use the inhaler correctly. Less than 10% of children with 
moderate or severe asthma were provided information about medication side effects or use 
of diaries. 
Preventive medication was prescribed for61.1% of the children with moderate or severe 
asthma and 27.1 % of the children with mild asthma. Children who were prescribed 
preventive medication were more likely to be provided information about avoidance of 
triggers aOR 2.38 (95% CI 1.37-4.12), or education about treatment goals aOR 3. I4 (95% 
CI 1.46-6.75), after adjusting for age and asthma severity. 39.9% of children with 
moderate or severe asthma were not prescribed preventive medication and were also less 
likely to receive information about the importance of avoiding triggers or education about 
asthma. There was no significant association between a prior emergency department visit or 
hospitalization and patient education being provided by the primary care providers. 
This study indicates a need for more patient education, provider training, and new 
approaches to ensure widespread implementation of the NIH recommendations by primary 
care providers.3 4 5 Other studies of the impact of the NIH guidelines on the emergency 
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department management of childhood asthma have also suggested that implementation of 
the guidelines may be limited." 7 
The study design did not include a sample size large enough to allow comparisons between 
the different managed care plans or profile the prescribing practices of individual 
prescribers. Asthma specialists prescribe preventive medications more frequently than 
primary care physicians8 9 and access to or co-ordination of care by specialists10 11 may 
have facilitated implementation of the NIH guidelines by some of the plans. 
This population-based study of Medicaid el igible children is restricted to children from low 
income families. It was not possible to compare the results from this Medicaid group with 
other patients attending these plans. The present study suggests there is limited 
implementation of the NIH recommendations even for a group known to be at particularly 
high risk of asthma-related hospitalization 1' or mortality. 13 1" 
The NlH guidelines advocate providing education to the patients and their family but there 
are some conflicting results about the effectiveness of providing very limited education to 
patients. One systematic review and meta-analysis of the published li terature on adults 
concluded that limited asthma education (information only) for adults reduced emergency 
department visits and improved knowledge but did not reduce hospitalizations or physician 
visits. 15 
One limitation of our study was the use of medical records to evaluate patient education as 
the quality of the education routinely provided could not be assessed. The extent of the 
education provided may also have been underestimated; for example the ability to use an 
inhaler may be checked by pharmacists and not recorded in the medical records. In 
addition , education may be provided to the patient but not documented in the medical 
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records by the health care provider. This study may have underestimated the amount of 
patient education provided, which could have biased the estimates of the associations 
towards the null value. 
The potential impact of providing appropriate patient education for children has been 
demonstrated. 16 A randomized control trial studied the impact over 12 months of an initial 
training program comprising five 1 hour sessions for the parents and children. This study 
found an increase in knowledge, compliance and reduced emergency room visits and days 
of hospitalization. 
Poor knowledge about asthma will make self-management difficult and lack of parental 
knowledge has been associated with readmission to hospital 17 18 19or emergency 
department visits.'0 21 For example, if the patients start or increase steroid medication at the 
onset of a cold or flu this has been shown to reduce the odds of an emergency department 
visit." There is also evidence to suggest that co-operation between health care providers, 
parents and children is essential to achieve optimal management.23 
Patient education was documented for less than half of the children during 1994, regardless 
of the type of education. The findings of the present study suggest that provision of patient 
education by primary care providers was associated with asthma severity. However, less 
than a quarter of the children with moderate or severe asthma were documented in the 
medical records as being provided information on the goals of treatment or having the 
ability to use the inhaler correctly confirmed. In addition, over half of the children 
prescribed inhaled anti-inflammatory medication were not provided information about 
avoidance of triggers. Poorly controlled asthma is estimated to account for approximately 
30% of the direct medical costs of asthma24 and also results in many social costs to the 
children and their family , for example by causing absenteesim from school." Nearly two 
39 
thirds of the ambulatory care visits for asthma are to primary care providers ratherthan 
asthma specialists.' 6 We conclude therefore that the limited implementation of the NIH 
recommendations by primary care physicians in our study has substantially reduced the 
impact of the NIH guidelines on the management of poorly controlled childhood asthma. 
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Table 1 Descriptive statistics and bivariate relationships between 
demographic characteristics, asthma severity, prior clinical events or 
medication prescribed and providing action plans or advice on avoidance 
of triggers 
Characteristics Total Action plan for Avoidance of 
exacerbations triggers 
n % n % n % 
Total 311 130 41.8 76 24.4 
Age (years) 2-4 92 29.6 31 33.7 .06 15 16.3 .03 
5-19 219 70.4 99 45.2 61 27.9 
Gender Female 146 47.3 60 41.1 .74 32 21.9 .30 
Male 163 52.8 70 42.9 44 27.0 
Asthma severity 
Mild 129 50.6 52 40.3 .00 30 23.3 .00 
Moderate 92 36.1 51 55.4 27 29.4 
Severe 34 13.3 26 76.5 18 52.9 
Preventive medication 0 190 6 l.l 59 31.1 .00 32 16.8 .00 
>= I 121 38.9 71 58.7 44 36.4 
Oral steroid course 0 246 79.1 95 38.6 .03 51 20.7 .00 
>=I 65 20.9 35 53.9 25 38.5 
Emergency visit 0 253 81.4 97 38.3 .20 57 22.5 .38 
>=I 58 18.7 17 29.3 JO 17.2 
Hospital admission 0 290 93 .3 122 42. l .LO 70 24.J .13 
>=I 21 6.8 5 23.8 2 9.5 
Bonfcrroni test for significance p-value=<O.O l'.!5 
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Table 2 Descriptive statistics and bh•ariate relationships between 
demographic characteristics, asthma severity, prior clinical events or 
medication prescribed and reviewing the treatment goals or ability to 
use an inhaler 
Characteristics Total Goals of Ability to use 
treatment inhaler 
n % n % p n % p 
Total 311 42 13.5 49 15.8 
Age (years) 2-4 92 29.6 8 8.7 .II 16 17.4 .61 
5- 19 219 70.4 34 15.5 33 15.I 
Gender Female 146 47.3 16 11.0 .20 21 14.4 .50 
Male 163 52.8 26 16.0 28 17.2 
Asthma severity 
Mild 129 50.6 II 8.5 .00 18 13.6 . 12 
Moderate 92 36.1 22 23 .9 23 25.0 
Severe 34 13.3 8 23.5 7 20.6 
Preventive medication 0 190 61.1 12 6.3 .00 23 12.l .03 
>=I 121 38.9 30 24.8 26 21.5 
Oral steroid course 0 246 79.l 27 11.0 .01 35 14.2 .15 
>=I 65 20.9 15 23.I 14 21.5 
Emergency visit 0 253 81.4 27 10.7 .08 33 13.0 .62 
>= I 58 18.7 II 19.0 9 15.5 
Hospital admission 0 290 93 .3 36 12.4 .80 47 16.2 . 16 
>=I 21 6.8 3 14.3 4.8 
Bonferroni test for significance J>-Value=<D.0 125 
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Table 3 Multivariate adjusted Odds Ratios and 95 % confidence intervals (Cl) for the association 
between asthma severity, age, prescribing prenntive medication and receiving patient education 
Chamctcri stics Act ion plan A \'(1iUancc c1f triggers T rCJlmC'n l goals Abil ity tu use inhaler 
aOR e Cl aOR e Cl a OR e Cl aOR e Cl 
Model I: 
Preventive medication 1.88 .02 1.09-3.24 2.38 .00* 1.37-4. 12 3. 14 .00* 1.46-6.75 1.49 .25 0.76-2.93 
Severity 1.85' .00* 1.25-2.75 3.61' .00* 1.69-7.72 3. 12 c .00* 1.45-6.72 2.35 c .0 1* 1.20-4.6 1 
Age >=5 years 1.77 .05 1.00-3. 16 1.8 1 .08 0.94-3.48 1.78 . 19 0.76-4. 18 0.81 .54 0.41-1.59 
""' 
""' Model 2: 
Oral steroid <..-oursc 1.97 .02 1. 13-3.45 2.62 .(XI* 1.43-4.77 2 .63 .0 1 * 1.29-5.36 1.64 . 17 0.82 -3.27 
A gc >=5 years 1.73 .04 1.03 -2.89 2.20 .02 1.1 6-4. 19 2. 13 .07 0.93-4.88 0.88 .M> 0.45- 1.<>9 
Model 3: 
Emergency visi t 0.79 .47 0.42- 1.49 0.84 .66 0.39-1.80 2.49 ,()3 1.11 -5.55 1.21 .64 0.54-2.74 
Age >=5 years 2.22 .0 1* 1.27-3.88 2. 18 .03 1.09-4.33 2.99 .02 1.1 7-7.65 0.96 .9 1 0.47-1.97 
Asthma severity code: 'O=Mi ld l=Mcxlemte 2= Severe '<>=Mil <l & mcxlemle I= Severe 'O=Mi l<l l=Mnderale & severe 
*Bonfcrroni tes t for significance p-value=<O.O 125 
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4B 
Divergence from NIH guidelines for pharmacologic therapy and risk of 
adverse outcomes in asthmatic children : a historical cohort study 
ABSTRACT 
Objective: To determine if the implementation of NIH guidelines for the treatment of 
moderate or severe childhood asthma with preventive anti-inflammatory medication 
(inhaled corticosteroids, cromolyn or nedocromil ) reduced the risk of severe asthma 
exacerbations. 
Design: Non-concurrent cohort study. 
Setting: 9 Medicaid managed care plans in the northeastern USA. 
Subjects: 311 children (aged 2-19 years) who were treated for asthma during the period 
January 1993 to December 1994. 
Main outcomes: Admission to hospital , emergency department visit or a course of oral 
corticosteroids. 
Results: Cox regression analyses were conducted with time dependent covariates for 
being prescribed preventive medications and adjusting for asthma severity (mild, moderate 
or severe), with a fixed covariate for age. Children diagnosed with moderate or severe 
asthma at least once who were prescribed preventive medication were less likely to require 
a course of oral steroids (Hazard Ratio 0.42 95% Cl 0.19-0.95), after adjusting for age and 
asthma severity. No significant association was found between prescribing preventive 
medications and hospital admission or an emergency department visit. 
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Conclusions: Prescribing preventive medication to children with moderate or severe 
asthma reduced the risk of exacerbations requiring a course of oral steroids. This study 
suggests that primary care physicians prescribing anti -inflammatory medication in 
accordance with the NIH guidelines may improve the clinical outcomes for children with 
moderate or severe asthma. 
50 
INTRODUCTION 
Asthma is the most common chronic childhood illness in the US 1 affecting 6.9% of 
children and is the fourth leading cause of disability in children.' In 1991 an Expert Panel 
prepared NIH guidelines for the diagnosis and management of asthma.3 The Expert Panel 
recommendations were updated in 1997 and continued to emphasize the role of 
inflammation in the pathogenesis of asthma.' The panel outlined an approach to asthma 
therapy that has four components: patient education, environmental control. comprehensive 
pharmacologic therapy and objective monitoring of the asthma severity. 
Daily long term preventive anti-inflammatory medications (such as inhaled corticosteroids, 
cromolyn sodium or nedocromil ) are recommended by the NIH guidelines for persistent 
asthma . Children consistently requiring symptomatic treatment more than twice a week 
(classified as moderate or severe asthmatics) should be given daily anti-inflammatory 
therapy. In addition , appropriate medications to manage acute asthma exacerbations (beta-
agonists and oral corticosteroids) should also be prescribed. 
Primary care physicians have multiple opportunities to implement the NIH guidelines, to 
monitor asthma severity, and adjust the pharmacotherapy. This study determined whether 
the implementation of NIH guidelines for the treatment of moderate or severe childhood 
asthma by primary care physicians prescribing preventive anti-inflammatory medication 
(i nhaled corticosteroids, cromolyn or nedocromil) reduced the risk of severe asthma 
exacerbations. Severe asthma exacerbations were measured by a hospital admission , 
emergency department visit or a course of oral steroids from the primary care physician. 
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METHODS 
Data source and study population 
The data analyzed were from a sample of 311 children (aged 2- 19 years) treated for asthma 
during 1994 in a Medicaid program in the northeastern USA. 
Medication and clinical data were requested from 9 managed care plans. Each plan was 
requested to identify all Medicaid members who were diagnosed and treated for asthma 
during 1994 (International Classification of Diseases, Ninth Revision, Clinical modification 
code ICD-9---493), and select a random sample of .SO children (aged 2 to 19 years in 1994) 
for study. The plans provided 388 medical records and 347 were eligible after verifying 
the patient's age on I st January 1994 was between 2 to 19 years old (41 were less than 2 
years old). 311 were eligible after confirming there was a visit with documentation of a 
prescription for an asthma medication during 1994 (36 out of 347 did not have 
documentation of a visit during 1994). 
The data on asthma treatment provided by plan primary care physicians between I st 
January 1993 and 31st March 1995 were abstracted from the medical records. Medication 
data abstracted included all the asthma medications prescribed (product name, route, 
directions, days supply), date prescribed and prescriber (primary care physician or other). 
The clinical data included the date of each physician visit, an assessment of the asthma 
severity at each visit, date of birth, gender, date of initi al asthma diagnosis, date of latest 
theophylline level, date of latest influenza vaccination, and types of patient education 
provided at each visit (ability to use peak flow meter, ability to use inhaler, how to use 
inhaler, side effects of medication, avoidance of triggers, action plan for exacerbations, use 
of diaries, and goals of treatment). For each visit there was also a record of height, weight, 
blood pressure, a physical examination, medical history (symptoms and functional status), 
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objective measures of lung function (peak expiratory flow rates, home use of a peak flow 
meter, spirometry results) and referrals to specialists {dates, type of specialist, reason). 
The clinical outcomes extracted from the medical records included asthma-related hospital 
admissions or emergency department visits (admission dates, discharge dates and reason 
for visit or admission). A primary care physician visit resulting in the prescription of a 
course of oral steroids was also considered. 
Procedures 
A data collection instrument and abstracting instructions were provided to nurses who 
reviewed the members' medical records, and hospital or emergency department encounter 
files. For each primary care physician visit the nurse reviewer abstracted the data 
requested, such as asthma severity, patient education and asthma medications prescribed. 
The nurse used the information in the medical records and the NIH guidelines to classify 
the asthma severity at each physician visit as mild , moderate or severe asthma. According 
to the clinical characteristics described in the NIH guidelines, mild asthmatics have 
infrequent, mild exacerbations which can be up to twice a week which are generally of 
brief duration. Moderate asthmatics have symptoms twice or more per week, the 
exacerbations may last several days and occasionally require emergency care. Severe 
asthmatics have continuous symptoms, limited activity levels, frequent nocturnal 
symptoms, and occasional hospitalization and emergency treatment. 
Asthma severity was coded as mild ( 1 ), moderate (2) or severe (3) at each physician visit. 
The maximum asthma severity recorded before the first event of the outcome under 
evaluation was used to divide the children into mild, moderate and severe asthmatics. 
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Asthma medications were coded as beta-agonists (oral or inhaled). preventive anti-
inflammatory medications (inhaled corticosteroids, inhaled cromolyn or nedocromil), oral 
theophylline or oral corticosteroids. The children were coded as receiving undertreatment 
at a visit where the asthma severity was moderate or severe and no preventive medications 
were prescribed. 
Prescribing anti-inflammatory medications in accordance with the NIH guidelines was 
determined by the following dichotomous variables: preventive medication (prescribed at 
least once), preventive medication prescribed at 50% or more of the visits when other 
asthma medications were prescribed, undertreatment (preventive medication was not 
prescribed at least once when the children visited the primary care physician with moderate 
or severe asthma) or undertreatment at 50% or more of the visits when other asthma 
medications were prescribed. 
The age on I st January 1994 was calculated and coded in four categories (2 to 4 years, 5 to 
7 years, 8 to 11 years and 12 to 19 years). In addition the multivariate analyses included 
age coded as two dichotomous variables. After establishing that the associations were not 
Ii near for each outcome, age was coded as 2 to 4 years and 5 to 19 years for an emergency 
department visit and a course of oral steroids or 2 to 7 years and 8 to 19 years for a hospital 
admission. 
The seasons were coded as a dichotomous variable for each physician visit. The fall-winter 
season was coded as I st October to 31st March. 
For the descriptive analyses the beginning of person-time for an individual was defined as 
the date of the first physician visit when an asthma medication was prescribed between I st 
January 1993 and 31st December 1994. The end of person-time was defined as the first 
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date forthe outcome under evaluation afterthe first physician visit (either a hospital 
admission or an emergency department visit for asthma or a course of oral steroids) or the 
end of the study period (3 I st December I 994). Person-time and events after the first event 
of the outcome under evaluation were therefore censored and not evaluated. 
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STATISTICAL ANALYSES 
Descriptive statistics and bivariate analyses 
Descriptive statistics were used to document the age, gender, asthma severity. medications 
prescribed and clinical outcomes for these 31 l children treated for asthma during 1994. 
Emergency deparrment visirs, hospiral admissions or course of oral sreroids 
Hospital admission, emergency department visit or course of oral steroids per person-year 
were calculated and documented by the following independent variables: age group, gender 
and asthma severity before the outcome under evaluation. The incidence density ratio 
(!DR) was calculated for each age group relative to the 2 to 4 year olds. The !DR were 
calculated for each asthma severity relative to the mild asthmatics. 
ln addition the bivariate relationship was evaluated between the event rates and prescribing 
preventive medication to children with moderate or severe asthma before each outcome. 
The !DR were calculated for each outcome relative to the children that received no 
preventive medication or no undertreatment. 
Prevenrive medicarionand underrrearmenr 
Preventive medication and undertreatment (for moderate and severe asthmatics) per person-
year were calculated and documented by the following independent variables: age group, 
gender and asthma severity before each outcome. The incidence density ratio (!DR) was 
calculated for each age group relative to the 2 to 4 year olds. The !DR were calculated for 
each asthma severity relative to the mild asthmatics for preventive medication and moderate 
asthmatics for undertreatment. For each outcome children were identified who had a visit 
with moderate or severe asthma before the event. The !DR were calculated relative to the 
chi ldren that had no event for each outcome. 
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Multivariate analyses 
For each outcome, Cox's regression method' was used to determine adjusted hazard ratios 
and 95% confidence intervals (Cl) for exposure to preventive medication or 
undertreatment, both when coded as fixed covariates or as time-dependent covariates. 
The fixed covariates were exposure to preventive medication or undertreatment, or a fixed 
covariate for exposure to preventive medication or undertreatment at the last visit in the 
study or before the event as appropriate. The fixed covariate analyses selected children 
with moderate or severe asthma before the outcome and used the time from the first visit 
when asthma medication was prescribed to the event or 31st December 1994. 
The analyses also included time dependent covariates for preventive medication , 
undertreatment, asthma severity (mild= I, moderate=2 or severe=3), and season. The time 
dependent analyses used the time from the first visit with moderate or severe asthma when 
asthma medication was prescribed to the event or 3 lst December 1994. 
Multivariate adjusted hazard ratios and 95% confidence intervals (CI) were calculated for 
each clinical outcome. The analyses all included a fixed covariate for age. 
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RESULTS 
Descriptive and bivariate results 
Emergency deparrment visits, hospital admission or course of oral steroids 
Frequency distributions of demographic characteristics, asthma severity, medications 
prescribed, emergency department visits, hospital admissions and a course of oral steroids 
are summarized in Tables 1-2. 
Emergency department visits were made at a rate of 0.260 per person-year, with a 
significantly higher rate for children with severe compared to mild asthma (0.573 per 
person-year) and for children aged 2 to 4 years when compared to older age categories 
(0.437 per person-year). The results from the bivariate analyses showed that children were 
more likely to make an emergency department visit if they were aged 2 to 4 years (Table I) 
or experiencing severe compared to mild asthma exacerbations (!DR 2.2 95% Cl I .2-3 .9, 
p-value 0.00). 
Hospital admissions were at a rate of 0.094 per person-year and did not change 
significantly with disease severity or decreasing age group. 
Oral steroid courses were prescribed to children with severe asthma exacerbations at a rate 
of 0.217 per person-year and the rates did not significantly differ between mild or moderate 
asthmatics. Oral steroid courses were prescribed at a significantly higher rate to children 
aged 8 to l l years old (!DR l.8 95% Cl l.l-3.5, p-value 0.04). 
Prescribing preventive medication to children with moderate or severe asthma was 
associated with a significantly reduced risk of being prescribed a course of oral steroids, 
(!DR 0.4 95% Cl 0.2-0.7, p-value 0.00) (Figure 1, Table 2). The rates were also reduced 
although not significantly for hospital admissions, (!DR 0.5 95% CI 0.2- 1.2, p-value 
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0.06) and emergency depanment visits (!DR 0.7 95% Cl 0.4-1.4. p-value 0. 17), (Figure 
l , Table 2). 
Undenreatment at 50% or more of the visits was associated with a significantly increased 
rate of prescribing a course of oral steroids (!DR 2.6 95% Cl 1.0-6.4, p-value 0.02) 
(Table 2). Undenreatment was not associated with significantly increased emergency 
department visit rates or hospital admission rates (Figure 2, Table 2). Gender was 
uniformly not a significant predictor of the clinical outcomes. 
Preventive medical ion and undertreatment 
Preventive medication was prescribed at a rate of0.828 per person-year to the children with 
severe asthma, 0.614 per person-year to the children with moderate asthma and 0.270 of 
the children with mild asthma (Table 3). The results from the bivariate analyses showed 
that moderate or severe asthma exacerbations before each outcome were significant 
predictors of preventive medication being prescribed (Table 3). Moderate asthmatics were 
not significantly more likely to be undertreated than severe asthmatics (Table 4) . Gender 
and age were not significant predictors of prescribing preventive medication or 
undertreatment (Tables 3-4). 
The preventive medication prescribing rates for children with moderate or severe asthma 
before the event were not significantly lower before an emergency depanment visit, 
hospitalization or a course of oral steroids (Table 5). The analyses suggest that there was 
significantly more undertreatment amongst children with moderate or severe asthma before 
an emergency department visit (!DR 1.8 95% Cl 1.2-2.8, p-value 0.01 ) or a course of oral 
steroids (!DR 2.6 95% Cl l.6-4.3 , p-value 0.00) but not before hospitalization (Figure 3, 
Table 5). 
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Multivariate analyses 
Hazard Ratios (HR) for the association between preventive medication and an emergency 
department visit, hospital admission or a course of oral steroids for children with moderate 
or severe asthma are presented in Table 6. 
Prescribing preventive medication to children with moderate or severe asthma was 
associated with a significantly reduced risk of a course of oral steroids in both a) the fixed 
covariate analyses for prescribing preventive medication at the last visit before the event 
(HR 0.26 95% Cl 0.09-0.77, p-value 0.02), after adjusting for age and b) the time 
dependent covariate analyses for prescribing preventive medication (HR 0.42 95% Cl 
0.19-0.95, p-value 0.04), after adjusting for age and asthma severity (Figure 4). 
Prescribing preventive medication was not associated with a significantly reduced risk of an 
emergency department visit after adjusting for age, asthma severity and an interaction with 
season. Periods of moderate or severe asthma were associated with a significantly higher 
risk for an emergency department visit (moderate asthma HR 1.96, 95% Cr 1.11 -3.47, and 
severe asthma HR 3.86 95% Cr 2.88-5. 16, p-value 0.03, after adjusting for age and 
preventive medication). 
A course of oral steroids (unadjusted HR 2.4, 95% Cr 1.3-4.4, p-value 0.0 I) and asthma 
severity (unadjusted HR 2.1, 95% Cl 1.2-3.7, p-value 0.01) when coded as time-
dependent covariates, were also associated with a significantly increased risk of an 
emergency department visit. 
The multivariate analyses of children with moderate or severe asthma indicated a 
significantly increased risk of an emergency department visit or a course of oral steroids 
with undertreatment (Table 7). Undertreatment was associated with a significantly 
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increased risk of a course of oral steroids in both a) the fixed covariate analyses for 
undertreatment at the last visit priorto an event if one occurred (HR 5.0 I, 95% Cl 1.99-
12.65. p-value 0.00), after adjusti ng for age and b) the time dependent covariate analyses 
(HR 2.53 , 95% Cl 1 15-5.58, p-value 0.02), after adjusting for age and asthma severity 
(Figure 5). 
Undertreatment was associated with a significant ly increased risk of an emergency 
department visit in the fixed covariate analyses for undertreatment at the last visit prior to an 
event if one occurred (HR 2.08, 95% CI 1.03-4.20, p-value 0.04). The time dependent 
analyses showed asthma severity was associated with an increased risk for an emergency 
department visit (moderate asthma HR 2.12. 95% CI 1.20-3.72, and severe asthma HR 
4.48. 95% CI 3.36-5.97, p-value 0.01 after adjusting for age and undertreatment). 
No significant results were obtained for an association between prescribing preventive 
medication and reducing the risk of hospital admission (Table 6). There was an increased 
but not significant association between undertreatment at the last visit prior to an event if 
one occurred and hospitalization (HR 2.45, 95% CI 0.91 -6.62, p-value 0.08) (Table 7). 
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DISCUSSION 
The results of this study suggest that the NIH guidelines for the use of preventive 
medications were implemented by the primary care physicians on at least one occasion to 
39.9% of the children in this study. Amongst the children with moderate or severe asthma 
during this study, 65.4% were not prescribed preventive medication on at least one 
occasion when they attended the primary care physician with moderate or severe asthma. 
The pattern of prescribing in this study is not consistent with full implementation of NIH 
guidelines, which support regularly prescribing preventive anti -inflammatory medication to 
children with moderate or severe asthma. 
This study shows that prescribing preventive medications by primary care physicians in 
accordance with NIH guidelines was associated with improved clinical outcomes in this 
study population. Severe asthma exacerbations requiring treatment with a course of oral 
steroids were reduced by more than half amongst the children prescribed preventive 
medication HR 0.42 (95% CI 0.19-0.95) (Figure 4 ). Multivariate analyses also showed 
that there was 2.5 times the risk of a subsequent course of oral steroids, among those with 
undertreatment (Figure 5). Undertreatment at the last primary care physician visit before an 
emergency department visit or a course of oral steroids was also associated with a 
significantly increased risk of both these adverse outcomes. 
Undertreatment on at least one primary care physician visit was approximately twice as 
common in children attending the primary care physician with moderate or severe disease 
before an emergency department visit or before receiving a course of oral steroids (Figure 
3). This study did not show a significant association between undertreatment and either a 
hospital admission or an emergency department visit (Figures 2 and 5). This study did 
however indicate that the primary care physicians could be prescribing preventive 
medications to more of the moderate or severe asthmatics. The high rates of emergency 
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department visits. hospital admissions and courses of oral steroids showed the impact of 
severe asthma exacerbations on the health of these children. Undertreatment is a modifiable 
risk factor for acute asthma exacerbations that could be successfully changed by the 
primary care physicians fully implementing the NIH guidelines. 
Other studies of asthmatic children have reported more under-use of preventive medication. 
A study was conducted by Kaiser Permanente Medical Care Program in California of 
children hospitalized or attending the emergency department as a result of severe asthma 
between January-July 1995. The study reviewed the medications prescribed to children 
attending a physician within 30 days of the hospital admission or emergency department 
visit: over 73% were prescribed a beta-agonist, 47% a course of oral steroids but only up to 
49% were prescribed cromolyn or inhaled steroids.• Under-use of preventive medications 
was also found amongst asthmatic children (48% were Medicaid patients) attending the 
emergency department of an inner city academic pediatric hospital in Pennsylvania during 
1994: 35% were previously ever prescribed cromolyn and 22% ever prescribed inhaled 
steroids.7 A questionnaire completed by the families of392 asthmatic children living in the 
inner city, revealed that only 11 % were receiving preventive medication. Selecting 166 
children with more severe asthma exacerbations requiring an emergency room visit in the 
past six months, the authors found that even in 1992 over 50% were under-treated and 
were not receiving preventive medication.• 
The results from the current study are also consistent with two studies using claims data 
bases which supported the suggestion that inhaled corticosteroid therapy caused a 
significant reduction in health care service use by asthmatic children, including Medicaid 
enrollees. One study reported asthma medication claims data from 6035 insured (non-
Medicaid) asthmatic children, the study was published by a New England based health 
maintenance organization, Harvard Pilgrim Health Care (HPHC). The HPHC results 
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showed the percentage of asthma prescriptions dispensed for preventive medications 
between October 1991 and September 1994 was respectively as follows: beta-agonisrs 
67%, cromolyn 16% and inhaled steroids 11 %. theophylline 6%! The study by HPHC 
demonstrated that preventive medications confer significant protection against exacerbations 
of asthma leading to hospitalization, but did not investigate other clinical outcomes. 
A retrospective case-control study of asthmatic Medicaid children (less than 12years old) 
used a North Carolina claims database to follow the health care costs of85 cases and 72 
controls for I year. 10 11 The cases began inhaled corticosteroid therapy between March 
1994 to 1995. The controls were on asthma therapy other than steroids for a continuous 2-
year period between March 1993 to March 1996. The study demonstrated that tbe 
introduction of inhaled corticosteroid therapy to Medicaid children was associated with a 
significant reduction in the total health care costs (hospitalizations, physician visits, 
outpatient visirs and the cost of medications). 
Many of the drugs for asthma can appear to increase risk of adverse outcomes because the 
patients for whom asthma medications are prescribed may have an increased risk of 
frequent and severe asthma exacerbations." The benefits of prescribing preventive 
medication were not always evident in the current study ifthe analyses did not adjust for 
asthma severity. Consequently to address confounding by asthma severity, the multivariate 
analyses used Cox regression which provided flexibility in the way the asthma severity and 
preventive medication were coded. The analyses could select the chi ldren attending with 
either moderate or severe asthma before the outcome and include severity as a time 
dependent covariate. The Cox regression analyses used both fixed covariates and time 
dependent covariates to measure exposure to preventive medication or undertreatment of 
children with moderate or severe asthma before each event. Cox regression also allowed 
the models to include time dependent variables recorded at irregular intervals for preventive 
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medication and severity recorded before the outcome being evaluated. 
The observed confidence intervals for associations were often wide because the sample of 
patients with a moderate or severe asthma before the emergency department visit or hospital 
admission was small. In the bivariate analyses emergency department visit rates were 
much higher in the group with outbreaks of severe disease. There were about 40 chi ldren 
in our sample classified as experiencing severe exacerbations and 56 that received a course 
of oral steroids and this therefore limited our analyses. 
A course of oral steroids is recommended by the NIH guidelines for the acute treatment of 
severe asthma exacerbations and therefore may have compensated for the risk of adverse 
outcomes from undertreatment with inhaled anti-inflammatory medication. For example, 
one study showed starting or increasing steroid medications at the onset of a cold or flu 
reduced the odds of asthmatic children making an emergency department visit.6 Emergency 
department visits were shown in our multivariate analyses to be consistently associated 
with prior severe asthma exacerbations or a course of oral steroids. If a course of oral 
steroids is considered a surrogate marker for an exacerbation of asthma severity, as 
preventive medication reduces the number of severe exacerbations there may also be a 
substantially greater potential to reduce emergency department visits than has been evident 
in this small sample. 
In our study emergency department visits were more common amongst 2 to 4 year olds. 
The NJH guidelines recognize this age group is less likely to be able to successfully co-
ordinate inhaling preventive medication, and may have to rely instead on courses of oral 
steroids for acute exacerbations. The 0 to 4 year age group bas been found to exhibit 
higher hospitalization rates for asthma than other age groups" 14 and there is an association 
between children aged 2 to 4 years old making more emergency department visits. 15 16 
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Hospital admission was less common than an emergency department visit and the rates 
appear not to be associated with severity, thus in this small sample the children were not 
always attending the primary care physician with moderate or severe disease before being 
admitted. The complexity of asthma risk factors may have prevented the association 
between undertreatment and admissions to hospital being detected in this sample size and 
duration. The triggers for each patient may be different and asthma severity fluctuates, 
there may be many periods when although preventive medication is not prescribed the 
asthma severity may not deteriorate to require an emergency department visit or 
hospitalization. In addition, ifthe children are taken to the physician with severe asthma a 
course of oral steroids will in many instances prevent hospitalization or an emergency 
department visit being necessary . Hospital admissions in this study were also seasonal 
(zero between July and September) and this may also explain the lack of association with 
undertreatment in this study. 
One predisposing factor for emergency department visits or hospital admissions seems to 
be the season of the year as more events were recorded during fall or winter. Similar 
results have also been recorded in other studies and viral infections have been suggested as 
a possible explanation for these seasonal trends." Viral infections aggravate clinical 
asthma and increase airway responsiveness that may persist for weeks after the infection. 18 
For example, two studies on asthmatic children reported the most common symptom 
experienced prior to the emergency department visit was wheezing induced by respiratory 
infections (over75%).7 19 In our study, the reasons for the emergency department visits 
and hospital admissions were not recorded in detail. For example, it was not known 
whether a viral infection was considered the trigger forthe acute exacerbation or an indoor 
allergen. 
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The information collected from chis Medicaid asthmatic population may not be generalizable 
to other children. There could be differences in prescribing practices or attendance at the 
physician office for preventive care visits by Medicaid patients. The managed care plans 
guarantee access for these Medicaid patients but there are many differences between poor 
minority families and health care providers that may influence prescribing practices for 
example language, cultural barriers, or literacy levels-'° Asthma may be viewed by families 
as ··episodic" rather than needing regular attendance at the physician for preventive 
medications. The study design did not include a sample size large enough to allow 
comparisons between the prescribing practices and outcomes from each of the nine 
different managed care plans or profile individual primary care prescribers. 
The race of the chi ldren in the current study was not known but it is possible some of the 
minority children are under-utilizing the primary care physicians. Studies of Medicaid 
asthmatic children have showed that African-American children have significantly fewer 
primary care physician visits than their white counterparts even after adjusting for potential 
confounding variables, suggesting under-use of preventive services for asthma." 22 A 
racial disparity may therefore exist in access to effective management of chronic asthma. 
Indoor allergens, such as cockroaches as well as dust mites or pets are now recognized as 
important triggers, which may be important amongst children living in poor housing 
conditionsn It was not known whether these children were living in inner city homes or 
rural conditions. 
A disproportionate number of poor children have been shown to rely on the emergency 
department instead of primary care providers for their asthma care.7 2 2 24 Higher 
hospitalization rates for asthma have been recorded for poor or minority children." 26 For 
example, a study of hospital discharge data from asthmatics less than 25 years old showed 
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that black patients were five times more likely than white to be hospitalized for asthma and 
50% more likely to be readmitted.27 These patient and various health care system 
characteristics all pose challenges to Medicaid patients moving away from episodic 
attendance at the primary care physician ·s office or emergency department for crisis 
orientated. fragmented care for asthma exacerbations.' 1 28 29 30 
Rates for asthma prevalence are highest among children residing in inner cities and 
important risk factors for asthma-related mortality includes being poor or black.' 31 " 33 
The Medicaid eligibility criteria for this study means all the children were from poor 
families. It was not possible to compare the results from this Medicaid group with other 
patients attending these plans. In the present study medications were free for the patients: 
thus there was no cost incentive for patients to avoid having prescriptions dispensed for 
preventive medications. In addition, a study of asthmatic Medicaid recipients showed that 
trends in prescribing anti-inflammatory medications were consistent and parallel with 
changes observed in the general population.34 However, two cross-sectional studies of 
medication claims data have shown an association between underuse of inhaled steroids 
and lower income.35 36 This population based study of Medicaid eligible children provides 
valuable information about the effectiveness of the NIH recommendations in a sample from 
the group of children known to be at a high risk of adverse outcomes. 
An unusual aspect of this study was the collection of clinical data from primary care 
physician medical records. The asthma diagnoses were confirmed from the medical 
records and therefore the study did not have to rely solely on the ICD 9 coding for the 
diagnosis. In the past the diagnosis criteria have varied for classifying asthma severity but 
the NlH guidelines include a working definition of mild, moderate and severe asthma 
severity. Access to the medical records allowed the NIH guidelines to be used to classify 
the children as mild, moderate or severe asthmatics at each physician visit when an asthma 
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medication was prescribed. The analyses were then able to address confounding by asthma 
severity by stratified analyses and including a time dependent covariate for asthma severity 
in the model. Most previous studies focused on severe asthmatics or did not use either the 
NIH criteria or a clinical assessment of severity. relying instead on medication claims data 
to calculate beta-agonist use rates of children treated by primary care physicians. 
The information about prescribing medications was collected from the medical records 
rather than a separate medication claims database, consequently not all the prescriptions 
may have been actually dispensed or administered regularly as directed. Patient compliance 
is important for preventive medications to be beneficial and for children it may be especially 
complex as parents, school nurses and other carers may have to administer the medication. 
Many studies have identified poor compliance with preventive medication amongst 
preschool 37and school children 38as well as with adult asthmatics.39 40 Patient compliance 
was not measured in this study, therefore these data may underestimate the value of 
prescribing preventive medication to these children. 
The low socioeconomic status of these children means they might be unable to avoid some 
environmental triggers, have a higher frequency of severe asthma, and experience a lack of 
continuity of care more than insured children. The effectiveness of prescribing in 
accordance with the NIH guidelines was still however clearly demonstrated as preventive 
medication significantly reduced, and undertreatment of moderate or severe asthma 
significantly increased the risk of prescribing a course of oral steroids. 
Asthma is the most common chronic illness in children13 and is the most frequent cause of 
hospitalization among children41 and one of the leading causes of absenteeism from 
school.42 Mortality rates are low for asthma but poorly controlled asthma results in many 
social costs to the children in addition to the medical costs associated with high rates of 
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physician consultations and hospital admissions. This population-based study supports the 
effectiveness of prescribing preventive anti-inflammatory medication under conditions of 
actual use by a Medicaid population. This study shows that primary care physicians can 
improve the control of asthma by implementing the NIH guidelines and regularly 
prescribing anti-inflammatory medication for moderate or severe asthma. 
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Figure Bivariate relationship between 
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Figure 2 Bivariate relationship between 
undertreatment and clinical outcomes for 
children with moderate or severe asthma 
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Figure 3 Bivariate relationship between clinical 
outcomes and undertreatment of children 
visiting the primary care physician with 
moderate or severe asthma before the event 
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Figure 4 Adjusted Hazard Ratios (aHR) for 
preventive medication and clinical outcomes 
for children with moderate or severe asthma 
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Table I Descriptive statistics and bivariate relationships between demographic characteristics, asthma severity 
and clinical outcomes 
ID = Incidence Density x 102 (person-years) IDR=lncidence Density Ratio C=Cases 
Charnctcristics Emergency department \'i Si L Hospital admission Oml steroids course 
n (person- c ID IDR p n (person- c ID IDR p n (person- c ID IDR 
~ears) (95% CI) vcars) (95\l Cl) i ·ears) (95% CI) 
Total 31 1(254.03) 66 26.0 3 11 (277.83) 26 9.4 3 11 (257.97) 56 21.7 
Age '.!-4 years 92(70.98) 3 1 43.7 92(82.59) II 13.3 92(H2.33) 16 19.4 
5-7 years 82(72.49) 14 19.3 0.4 .<Xl 82(77.65) 8 10.3 0.8 .'.!9 82(69. 18) 15 2 1.7 I. I .38 
-.J 
(0.2-0.8) (0.4- 1.8) (0.5-2.4) 
Ol 8- 11 years 76(6 1.46) 9 14.6 0.3 .00 76(64.83) 4 6.2 0.5 .09 76(54.25) 19 35.0 1.8 .04 
(0.2-0.6) (0.2- 1.4) ( 1.1 -3.5) 
12- 19 years 6 1(49.09) 12 24.4 0.6 .04 6 1(52.77) 3 5.7 0.4 .09 6 1(52.2 1) 6 11 .5 0.6 . 13 
(0.3- 1.1 ) (0. 1- 1.5) (0.2- 1.5) 
Gender 
Female 146( I 18.25) 28 23.7 146( 125.82) 13 10.3 146( 11 8. 10) 24 20.3 
Male 163( 133.19) 38 28.5 1.2 .23 163( 149.42) 13 8.7 0 .9 .33 163( 138. 11 ) 3 1 22.5 I . I .36 
(0.8- 1.9) (0.4- 1.8) (0.6- 1.9) 
Asthma sc' crity 
Mild 144( 11 0.80) 29 26.2 136( 11 4. 13) 8 7.0 151( 122.93) 2 1 17. 1 
MotJcr~1t c 108(99.40) 16 16. I 0.6 .06 11 3( 106.65) 12 11 .3 1.6 . 15 105(92.6 1) 24 25.9 1.5 .08 
(0.3- 1.1 ) (0.7-3.9) (0.1! -2.7) 
SC \'CfC 40(31.40) 18 57.3 2.2 .IXJ 44(43 .72) 5 11.4 1.6 . 19 3 1(27.36) 2 7.3 0 .4 . 12 
(1.2-3.9) (0.5-4.9) (0.2- 1.2) 
Table 2 Descriptive statistics and bivariate relationships between preventive medication or undertreatmcnt and 
clinical outcomes for children with moderate or severe asthma 
ID = Incidence Density x IO' (person-years) IDR=Incidence Density Ratio C=Cases 
Characteristics Emcrgcni.;y department visit Hospita l admission Oral steroids course 
n (person- c ID IDR p n (person- c ID IDR p n (person- c ID IDR p 
'cars) ·cars) 'cars) 
T otal 148( 130.8) 34 26.0 157( 150.4) 17 I 1.3 136( 120.0) 26 2 1.7 
Preventi ve 
medication No 6 1(5 1.1 2) 16 31.3 58(52.58) 9 17.1 54(38.75) 15 38.7 
-.../ Yes 87(79.68) 18 22.6 0.7 . 17 991,97.79) 8 8.2 0.5 .06 82(8 1.22) 11 13.5 0.4 .<Kl 
-.../ (0.4-1.4) (0.2- 1.2) (0.2-0.7) 
>=.50% ,·isits 64(55.43) 14 25.3 0.8 .28 73(70.24) 6 8.5 0.5 .09 67(62.83) 10 15.9 0.4 .Il l 
(0.4-1.7) (0.2- 1.4) (0.2-0.9) 
Unt.lcru·eatmcnt 
No 47(39.46) 10 25.3 52(45.52) 5 11.0 47(44. 13) 6 13.6 
Yes 10 1(91.35) 24 26.3 LO .46 105( 104.85) 12 11 .4 1.0 .47 89(75.84) 20 26.4 1.9 .07 
(05-2.2) (0.4-2.7) (0.8-4.8) 
>=50% visits 60(50.69) 15 29.6 1.2 .35 56(55.6 1) 6 10.8 1.0 .49 56(45.88) 16 34.9 2.6 .()'.! 
(0.5-2.6) (0.3-3.7) ( 1.0-6.4) 
Table 3 Descriptive statistics and bivariate relationships between 
demographic characteristics or asthma severity before the event and 
preventive medication 
ID=Incidence Density x 10' (person-years) IDR=Incidence Density Ratio 
Characteristics Preventive medication 
n (person-years) Cases ID IDR p 
Total* 311 (257.97) 124 48.I 
Age* 2-4 years 92 (82.33) 32 38.9 
5-7 years 82(69.18) 34 49.2 1.3 (0.8-2. I) . 17 
8- 11 years 76 (54.25) 30 55.3 1.4 (0.9-2.3) .08 
12-19 years 61 (52.2 1) 28 53.6 1.4 (0.1- 1.7) .I I 
Gender* Female 146(118.10) 50 42.3 
Male 163 ( 138. 11 ) 72 52.I 1.2 (0.9-1.8) .13 
Emergency visit 
Mild 144 ( 110.80) 30 27.1 
Moderate 108 (99.40) 61 61.4 2.3 ( 1.5-3.5) .00 
Severe 40 (3 1.40) 26 82.8 3.1 ( 1.9-5.0) .00 
Hospital admission 
Mild 136 ( 150.37) 3 1 20.6 
Moderate 113 ( 106.65) 69 64.7 3.1 (2. 1-4.7) .00 
Severe 44(43.72) 30 68.6 3.3 (2. 1-5.3) .00 
Oral steroids course 
Mild 151 ( 122.93) 36 29.3 
Moderate 105 (92.61) 60 64.8 2.2 ( 1.5-3.3) .00 
Severe 3 1 (27.36) 22 80.4 2.7 ( 1.7-4.6) .00 
*Calculated before oral steroids course 
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Table 4 Descriptive statistics and bivariate relationships between 
demographic characteristics or asthma severity before the event and 
undertreatment for children with moderate or severe asthma 
ID = Incidence Density x IO' (person-years) 
IDR= Incidence Density Ratio 
Characteristics Undertreatment 
n (person-years) Cases ID IDR p 
Total* 136 (119.98) 89 74.2 
Age* 
2-4 years 44 (41.72) 32 76.7 
5-7 years 34 (27.71) 21 75.8 1.0 (0.6-1.7) .48 
8-1 lyears 30 (26.87) 21 78.2 1.0 (0.6-1.9) .48 
12-19 years 28 (23 .66) 15 63.4 0.8 (0.4-1.6) .30 
Gender* 
Female 61 (53.52) 42 78.5 
Male 74 (65.56) 47 71.7 0.9 (0.6-1.4) .33 
Emergency visit 
Moderate 108 (99.40) 74 74.5 
Severe 40 (31.40) 27 86.0 1.2 (0.8-1.8) .26 
Hospital admission 
Moderate 113 (106.65) 75 70.3 
Severe 44 (43.72) 30 68.6 1.0 (0.7-1.5) .46 
Oral steroids course 
Moderate 105 (92.6 1) 71 76.7 
Severe 31 (27.36) 18 65.8 0.9 (0.5-1.4) .28 
*Calculated before oral steroids course 
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Table 5 Descriptive statistics and bivariate relationships between an emergency department visit, hospital 
admission or course of oral steroids and preventive medication or undertreatment of children visiting the 
primary care physician with moderate or severe asthma before the event 
ID = Incidence Density x 10' (person-years) IDR= Incidence Density Ratio 
Characteristics Preventi ve medication Undertrealrnent 
n (person- Cases ID IDR p Cases ID IDR p 
years) 
Emergency visit 
CXl 
0 No 114 ( 111 .59) 69 61.8 77 69.0 
Yes 34 ( 19.21 ) 18 93.7 1.5 (0.9-2.6) .06 24 124.9 1.8 ( 1.2-2.8) .01 
Hospital admission 
No 140 ( 104.07) 91 87.4 93 89.4 
Yes 17 ( 10.30) 8 77.7 0.9 (0.4- 1.8) .38 12 11 6.5 1.3 (0.7-2.4) .19 
Oral steroids course 
No 110 ( 108.08) 7 1 65.7 69 63.8 
Yes 26( 11.88) II 92.6 1.4 (0.8-2.7) . 14 20 168.4 2.6 ( 1.6-4.3) .00 
" 
Table 6 Hazard Ratios (HR) and 95 % Confidence Intervals (Cl ) describing the association between 
preventive medication and an emergency department visit, hospital admission or course of oral ste roids for 
children with moderate or severe asthma 
Variable Emergency department \'isit Hospital admi ssion Or.i i steroids course 
HR p CI HR p Cl HR 0 CI 
Preventive medication 1.83 . 14 0.82-4.06 3.40 . 10 0.78- 14.97 1.71 .34 0.56-5.22 
Age* 0.42 .01 0.21 -0.84 0 .61 .32 0.22- 1.64 0 .66 .38 0.27- 1.65 
Pre' cntivc medication a t his t visi t 1.34 .40 0.68-2.65 0.63 .36 0.'.!3- 1.70 0 .'.!6 .O'.! o.m-o.77 
CD before c,·cnt 
Age* 0.44 .02 0.'.!'.! -0.86 0.63 .36 0.'.!3- 1.70 0.83 .69 0.34-2.(14 
Prc\'cntivc mcllicution prior to C\'Cnt** 1.31 .44 0.66-2.6 1 0.93 .89 0.33-'.!.64 0.4'.! .!14 0. 19-0.95 
Sc\'crit y* * Moderate 1.96 .02 1.11 -3.47 1.02 .99 0.45-2.3'.! I. II .74 060-'.!07 
SC\CfC 3.86 .0'.! '.! .88-5. 16 
Age* 0.59 . 15 0.29- 1.22 0.55 .'.!8 0. 19- 1.6 1 1.32 .52 0.57-3.07 
* Age-coding: >=5 years for emergency oepariment visits and ora l steroids & >=8 yea rs for hospi tal admissions 
**Ti me dependent covariate 
Table 7 Hazard Ratios (HR) and 95 % Confidence Intervals (Cl) describing the associations between 
undertreatment and an emergency department visit, hospital admission or a course of oral slcroids for 
children with moderate or severe asthma 
Variable Emergency department visi t Hospital admission Oral s teroids course 
HR p Cl HR p Cl HR p Cl 
Undertrcatmcnt 1.1 5 .73 0.52-2.55 1.1 0 .87 0.36-3.38 8 .13 .04 1.09-60.79 
Age* 0.46 .02 0.23-0.90 0.63 .37 0.23-1.7 1 0.79 .60 0.32- 1.93 
CXl 
I\) Undcrt rcatmcnt at last vi sit before event 2.08 .04 1.03 -4.20 2.45 .08 0.9 1-6.62 5.0 1 .(XJ 1.99- 1:!.65 
Age* 0.54 .09 0.21- 1.m 0.72 .53 0.26- 1. 99 0.82 .66 0.33-2.!Xl 
Undcrtrc<.i uncnt prior toc,·cnt** 0.75 .42 0.36- 1. 53 1. 27 .68 0.42-3.84 2.53 .02 1.1 5-5.58 
Severi ty** Moderate 2.12 .0 1 1. 20-3.72 0.94 .90 0.38-2.32 0.76 .47 0.37-1.59 
Sc"crc 4.48 .0 1 3.36-5.97 
Age* 0.59 . 15 0.29- 1.22 0.56 .28 0. 19- 1.63 1.33 .5 1 0.57-3.09 
* Age coding: >=5 years for emergency department visits and oral steroids & >=8 years for hospital admissions 
**Time dependent covariate 
( 
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PART2 
Part 2 incl udes the following appendices: 
Appendix A. Introduction and review of the problem 
Appendix B. Details of the methods 
Appendix C. Overview of major findi ngs 
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APPENDIX A INTRODUCTION AND REVIEW OF THE PROBLEM 
CffiLDHOOD ASTHMA 
Studies of childhood asthma indicate a prevalence range of between 0.5 to 6.3% in the 
USA.' Asthma is the fourth leading cause of disability' and the most common chronic 
disease of childhood.' Mortality rates are low for asthma but poorly controlled asthma 
results in many social costs to the children in addition to the medical costs.4 For example, 
asthma is one of the leading causes of absenteeism from school : a loss of more than 10 
million school days was estimated for 1990, resulting in lost productivity costs for the 
caregivers of $726 million.' Asthma is the most frequent cause of hospitalization among 
children and over the last 20 years pediatric hospitalization rates for asthma doubled." 
Asthma also leads to high rates of primary care physician consultations and emergency 
room visits.5 According to the 1988 National Health Interview Survey (N I-IIS) in a sample 
of children less than 18 years old, asthma was rated as severe, moderate and mild for 10%, 
32% and 59% of the children.7 However, the children with severe asthma account for 
27% of the days missed from school, 35% of the hospitalizations and 77% of the days in 
hospital.7 
Rates for asthma prevalence are highest among children residing in inner cities and 
important risk factors for asthma-related mortality include being poor or black.8 9 10 Higher 
hospitalization rates for asthma have also been recorded for poor or minority children.7 11 
For example , a study of hospital discharge data from asthmatics less than 25 years old 
showed that black patients were five times more likely than white to be hospitalized for 
asthma and 50% more likely to be readmitted. 12 Studies of Medicaid asthmatic children 
have shown that African-American children have significantly fewer primary care physician 
visits than their white counterparts, even after adjusting for potential confounding 
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variables. suggesting under-use of preventive services for asthma. 13 14 A racial disparity 
may therefore exist in access to effective management of chronic asthma. 
A disproportionate number of poor children have been shown to rely on the emergency 
department instead of primary care providers for their asthma care. 141 5 28 Many aspects of 
poverty may be increasing the risk of mortality , such as: Jack of access to high quality 
health care. Jack of continuity of care, decreased use of anti-inflammatory medications. 
housing with high levels of cockroach or dust mite antigens, poor systems of social 
support, and low education Jevels. 10 16 Both patient and various health care system 
characteristics all pose challenges to moving low income patients away from episodic 
attendance at the primary care physician ' s office or emergency department for crisis 
orientated, fragmented care for asthma exacerbations. " 17 18 19 The inner city in the US is 
inhabited by impoverished people who are disproportionately nonwhite so separating these 
risks has proved difficult, however some evidence currently suggests socioeconomic status 
is the more important risk factor than race for asthma morbidity. 10 
Studies of the prevalence of childhood asthma have shown that the prevalence of asthma 
changes during childhood with age and gender.' The prevalence of asthma is higher in 
boys Jess than 5 years old, with the distribution becoming more equal later in childhood, 
and among adults asthma is more common in women than menw 21 Amongst children 
with mild episodic asthma up to 60% will have an improvement in symptoms by 
adulthood, although less than 20% of chronic asthmatics will become asymptomatic.22 
The management of chronic asthma has changed in recent years with the increased 
recognition of the important role of the inflammatory component in the pathogenesis of 
asthma. The management of asthma currently includes both drug therapy and the 
avoidance of known allergens, monitoring Jung function with peak flow meters and a 
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greater emphasis on the importance of educating the patient and their family about asthma." 
Indoor allergens. such as cockroaches, dust mites. pets or cigarette smoke are now 
recognized as important triggers for asthma.'" 25 
Viral infections aggravate clinical asthma and increase airway responsiveness that may 
persist for weeks after the infection." ' 6 Consequently there are seasonal increases in the 
frequency of asthma attacks when the epidemic respiratory virus infections are in the 
community in the fall or when there are higher concentrations of airborne allergens. For 
example. studies on asthmatic children reported the most common symptom experienced 
prior to the emergency department visit was wheezing induced by respiratory infections 
(over 75%)27 28 and starting or increasing steroid medication at the onset of a cold or flu 
have been shown to reduce the odds of an emergency department visit. '° 
Research indicates approximately 30% of the direct medical costs of asthma are attributable 
to inadequately controlled disease.3° Nearly two thirds of ambulatory care visits for asthma 
do not involve asthma specialists but physicians from family medicine or general practice, 
pediatrics or internal medicine.5 Opportunities exist to optimize the treatment of asthma by 
primary care physicians and improve the patients quality of life, minimize the impact of the 
disease on the family and reduce the frequency and severity of acute exacerbations leading 
to hospitalization or emergency room visits. 
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NIH GUIDELINES FOR THE TREATMENT OF CHILDHOOD ASTHMA 
Summary of recommendations 
In 1991 an Expen Panel prepared NIH guidelines for the diagnosis and management of 
asthma.23 The ex pen panel outlined an approach to asthma therapy that has four 
components: patient education. environmental control, comprehensive pharmacologic 
therapy and objective monitoring measures to monitor the severity of disease and course of 
therapy. The Expen Panel updated the recommendations in I 997 and continued to 
emphasize the role of inflammation in the pathogenesis of asthma.31 The guidelines issued 
in 1997 advocated a stepwise approach, linking asthma severity with treatment alternatives 
and put an even stronger emphasis on anti-inflammatory medication. 
The NIH guidelines issued in 1991 defined three categories of asthma severity: mild , 
moderate or severe (Table I). The NIH classification of asthma severity is based on 
severity before optimal therapy is initiated. Asthma is highly variable, so the characteristics 
of each class are general and may overlap plus individuals can switch between categories 
over time. The updated guidelines issued in 1997 expanded the categories to four by 
dividing mild asthmatics into patients witb mild intermittent asthma or mild persistent 
asthma. The data extracted from the medical records related to the period between I 993 
and I 994 therefore this study used the criteria published in I 99 l to categorize the asthma 
severity and assess the appropriateness of the therapy prescribed. 
Daily long term preventive anti -inflammatory medications (such as inhaled corticosteroids, 
cromolyn sodium or nedocromil) are recommended for persistent asthma.23 Children 
consistently requiring symptomatic treatment more than twice a week (classified as 
moderate or severe asthmatics) should be given daily anti-inflammatory therapy. In 
addition, appropriate medications to manage acute asthma exacerbations (beta-agonists and 
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oral corticosteroids) should also be prescribed. The treatment recommended by the 1991 
guidelines can be summarized as follows: 
Mild asthma: 
Beta-agonise alone 
Cromol yn alone 
Beta-agonise and cromolyn 
Moderate asthma: Anti-inflammatory agents and bronchodilators 
Beta-agonist and inhaled steroid 
Severe asthma: 
Beta-agonist, cromolyn and inhaled steroid 
Beta-agonist and theophyiline 
As for moderate asthma with addition oi orai steroids and spacer device. 
The NlH guidelines recommend anti-inflammatory medications but indicate that 
theophyiiine can be prescribed for childhood asthma. Theophylline has a narrow 
therapeutic index so for a chi id over 5 years oid who needs maintenance medication, an 
inhaled steroid or cromolyn is considered the simplest and safest regimen." Slow-release 
theophylline does offer an alternative to inhaled corticosteroids when a patient complies 
poorly with a maintenance regimen oi inhaled steroids or cromoiyn and is judged more 
likely to adhere to an oral regimen. The NlH guidelines recognize the younger age group is 
less likely to be able to successfully co-ordinate inhaling preventive medication, and may 
have to rely instead on courses oi orai steroids for acute exacerbations. 
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Oral steroids are very effective anti-inflammatory medications but are reserved for severe 
asthma because of the risk of suppressing pituitary adrenal function and causing iatrogenic 
Cushings syndrome with the associated impairment of growth. bone formation and bone 
density. There is evidence to suggest that children receiving oral therapy also benefit from 
inhaled steroids-" The regular prophylactic use of inhaled steroids is the recommended 
therapy for moderate asthma, reducing the extent to which theophylline and oral steroids 
are prescribed.33 " There is substantial evidence to show that moderate doses of inhaled 
steroids do not impair growth and maturation because there is such a weak systemic 
effect.35 
Beta-agonist medications have been associated with controversy over whether high use was 
associated with an increased risk of fatal asthma. There have been numerous headlines 
about whether beta-agonists are associated with an increase in asthma deaths, however a 
full review of the evidence did not eventually support the initial concems.36 The studies 
concluded that the increased risk of fatal ornear fatal asthma was clinically important for 
adult patients who used > 1-2 cans of inhaler per month37 or for hospitalization for children 
using >8 inhalers per person-year.38 There is also evidence that in patients with mild 
asthma. neither deleterious nor beneficial effects derive from regular use of inhaled 
albuterol beyond those derived from use of the drug as needed.39 
The guidelines also emphasize the importance of patient education in the management of 
asthma and the potential benefits from environmental control. The guidelines recommend 
provision of action plans, information on avoidance of triggers, goals of treatment and 
ability to use an inhaler, use of diaries and side effects of medications. 
A written action plan to guide patient self-management is especially important for patients 
with moderate or severe persistent asthma and any with a history of severe exacerbations. 
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Asthma severity is highly variable and may change over time so assessment is 
recommended at least biannually. This allows the physician to check that treatment goals 
are being met and that the patient is on appropriate pharmacotherapy with up to date self 
management and action plans. The ability to use the inhalers correctly should also be 
checked to ensure maximum benefit from the medication prescribed, especially if asthma 
control is not achieved. 
Exposure of an asthmatic patient to inhalant allergens to which the patient is sensitive 
increases airway inflammation and symptoms. Substantially reducing such exposure will 
result in significantly reduced inflammation, symptoms and need for medication. Patients 
with asthma at all levels of severity are recommended in the NIH guidelines to receive 
education about the importance of minimizing exposure to inhalant triggers. The 
counseling should include how to control and avoid exposure to known allergens, cigarette 
smoke and to make reasonable attempts to reduce exposure to respiratory viruses. 
Implementation of recommendations for childhood asthma 
This study determines the extent to which the NlH recommendations have been 
implemented by the primary care physicians for children with asthma in a randomly 
selected population of Medicaid patients. The study summarizes prescribing of preventive 
medication, provision of patient education and information about environmental control. In 
addition the study identifies the demographic characteristics, clinical characteristics or 
events that are predictors of prescription of preventive medication or provision of patient 
education to children. 
Primary care physicians have multiple opportunities to implement the NIH guidelines and 
optimize the treatment by monitoring the asthma severity, pharmacotherapy and providing 
counseling on self-management of asthma. Evidence that guidelines influence patient care 
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is needed because their effectiveness in changing practice behaviors and improving health 
outcomes is widely questioned. "'° 41 42 Physician performance has been shown lo be 
improved by providing feedback on prescribing practice patterns which can also be used to 
support quality improvement initiatives targeting potential areas for change." -1-1 
The impact of the guidelines on clinical outcomes will depend on the effectiveness of the 
treatment recommended but also on the dissemination of the recommendations from the 
specialists to the primary care physicians. For example. asthma specialists have been 
shown to be more likely to prescribe preventive medications than primary care physicians4 5 
46 and access to or co-ordination of care by specialists"'"" may facilitate implementation of 
the NIH guidelines. 
The results from four recent studies focused on children with moderate or severe asthma 
have indicated that the NIH guidelines recommending the use of preventive medication 
have not been fully implemented. A study was conducted by Kaiser Permanente Medical 
Care Program in California of children hospitalized or attending the emergency department 
as a result of severe asthma between January through July 1995. The study reviewed the 
medications prescribed to children attending a physician within 30 days of the hospital 
admission or emergency department visit: over 73% were prescribed a beta-agonist, 47% a 
course of oral steroids but only up to 49% were prescribed cromolyn or inhaled steroids_,. 
Under-use of preventive medications was also found amongst asthmatic children ( 48% 
were Medicaid patients) attending the emergency department of an inner city academic 
pediatric hospital in Pennsylvania during 1994: 35% were previously ever prescribed 
cromolyn and 22% ever prescribed inhaled steroids.28 Similarly, a study of children 
hospitalized as a result of an asthma exacerbation found that at most 33% of the children 
hospitalized for asthma had received cromolyn or inhaled steroids before admission. 49 
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A questionnaire completed by the families of392 asthmatic children living in the inner city, 
revealed that only 11 % were receiving preventive medication. Selecting 166 children with 
more severe asthma exacerbations requiring an emergency room visit in the past six 
months, the authors found that even in 1992 over 50% were under-treated and were not 
receiving preventive medication.50 
The impact of guidelines on the treatment of a chronic disease such as asthma is dependent 
on sustained compliance with the recommendations. Low rates of repeat prescriptions for 
preventive medications have been detected in studies of adults and children. A study of 
moderate or severe asthmatics 51 (adults and children over 7 years old), showed 63% were 
dispensed preventive medications (but only 32% were receiving preventive medications 
regularly). Another study" also suggested less than 54% of the patients (adults and 
children over 12 years) prescribed anti-inflammatory medications were collecting the 
medications regularly. A study of British children indicated53 very few (less than 15%) 
were dispensed preventive medications regularly. 
The impact of these NIH guidelines on the emergency department management of 
chi ldhood asthma has also been studied54 55 and also revealed that implementation may be 
limited. A survey of physicians at academic medical centers with a pediatric residency 
program found that at most half of those surveyed believed their emergency management of 
asthma was influenced by the NIH guidelines.54 A survey of physicians based at a sample 
of children ' s emergency departments showed that45.5% had heard of the guidelines and 
24% had read them.55 
There are many challenges to moving towards providing preventive care for asthmatics and 
persuading patients not to only attend either the primary care physician ' s office or 
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emergency department for urgent care for acute asthma exacerbations.56 57 The lack of 
regular prescribing of preventive medications for some children may show a need for more 
patient education, provider training, and alternative disease management approaches to 
introduce the asthma treatment strategies recommended in the NIH guidelines.58 59 60 
Effectiveness of the Nm recommendations for the treatment of childhood 
The efficacy of anti-inJlammatory medications at reducing airway hyperresponsiveness was 
demonstrated in clinical trials and these results were the basis for development of the NIH 
guidelines.23 Few population based studies have been published on the effectiveness of 
anti-inflammatory medications for the treatment of childhood asthma. Many researchers 
have focused on severe asthmatics rather than the population treated by primary care 
physicians. This population based study reviews the effectiveness of primary care 
physicians prescribing preventive anti-inflammatory medications under conditions of actual 
use. 
Two studies using claims data bases have shown that inhaled corticosteroid therapy caused 
a significant reduction in health care service use by asthmatic children. One study reported 
asthma medication claims data from 6035 insured (non-Medicaid) asthmatic children, at 
Harvard Pilgrim Health Care (HPHC). The HPHC results showed the percentage of 
asthma prescriptions dispensed for preventive medications between October 1991 and 
September 1994 was respectively as follows: beta-agonists 67%, cromolyn 16% and 
inhaled steroids 11 %, theophylline 6%.38 The study by HPHC demonstrated that 
preventive medications confer significant protection against exacerbations of asthma leading 
to hospitalization, but did not investigate other clinical outcomes. 
A retrospective case-control study of asthmatic Medicaid children (less than 12 years old) 
used a North Carolina claims database to follow the health care costs of85 cases and 72 
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controls for 1 year.6 ' 62 The cases began inhaled conicosteroid therapy between March 
1994 to 1995. The controls were on asthma therapy other than steroids for a continuous 2-
year period between March 1993 to March 1996. The study demonstrated that the 
introduction of inhaled corticosteroid therapy to Medicaid children was associated with a 
significant reduction in the total health care costs (hospitalizations, physician visits, 
outpatient visits and the cost of medications). 
A cohon study of the relative risk of readmission to hospital by severe asthmatic patients 
(age 5-54 years) showed that using inhaled steroids reduced the risk of readmission during 
the period 16 days to 6 months after the first admission63 or of fatal or near fatal asthma n 
The studies have not however always demonstrated a protective effect for severe asthmatics 
of steroids from readmission of children""' or patients age (5-45 years) 65 to hospitals. 
The NTH guidelines recommend education to support self-management, although there are 
some conflicting results ex.isl about the efficacy of providing very limited education. Many 
of the education studies are however difficult to compare as there are few patients studied, 
and the nature of the intervention and duration all vary considerably. Positive effects on 
outcomes were found from some programs for children which were designed to promote 
knowledge and self-management in asthma. For example, a randomized control trial 
studied the impact over 12 months of an initial training program comprising five 1 hour 
sessions for the parents and children. This study found an increase in knowledge, 
compliance and reduced emergency room visits and days ofhospitalization.66 Reductions 
in hospitalizations and emergency room visits have also been obtained from introducing a 
pediatric outreach program for an inner city population that were identified as having a 
history of using these services.48 Another study of the benefits of introducing a program 
for inner city children only showed a significant effect of the program on children whose 
episodes of asthma were severe enough to have been hospitalized in the previous year.67 A 
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systematic review and meta-analysis of the published literature on adults concluded that 
limited asthma education(information only) for adults reduced emergency department visits 
and improved knowledge but did not reduce hospitalizations or physician visits.68 
There is evidence to suggest that co-operation between health care providers, parents and 
children is essential to achieve optimal management.69 Poor knowledge about asthma will 
make self-management difficult and lack of parental knowledge has been associated with 
readmission to hospital 70 71 or emergency department visits-" 73 Focus groups of urban 
minority asthmatic children in New York showed many parents and children had very 
modest expectations of symptom control.74 Asthma was viewed by the families as 
"episodic" increasing their emphasis on symptomatic treatment rather than for preventive 
visits. Many studies have identified poor compliance with preventive medication amongst 
preschool 75and school children 76as well as with adult asthmatics.53 7178 Consequently 
some organizations are experimenting with approaches to implementing the NlH guidelines 
which integrate patient education with careful co-ordination of medical management for 
acute and ambulatory care.57 5 8 79 
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Table 1 NIH guidelines (1991) criteria for classification of asthma by severity of disease 
Characteristics Mild Moderate Severe 
A. Pretreatment 
Frequency of Exacerbation of cough and Exacerbation of cough and Virtuall y daily wheezing. Exacerbations 
exacerbations wheezing no more often wheezing on a more frequent frequent , often severe. Tendency to 
than 1-2 times per week basis th an 1-2 times per week. have sudden severe exacerbations. 
Could have hi story of severe Urgent visits to hospita l emergency 
exacerbations, but infreq uent. departments or doctor ' s office >3 times 
Urgent care treatment in hospita l per year. Hospitali zati on >2 times per 
emergency department or year, perhaps with respiratory 
doctor 's office <3 times per year. insufficiency or, rarely, respiratory 
failure and hi story of intubation. May 
have had cough syncope or hypoxic 
seizures. 
Table I (continued) NIH guidelines (1991 ) criteria for classification of a sthma by seve rity of disease 
Characteris ti cs -- Mil_d ___ Moderate Severe 
Frequency of Few clinical signs or symptoms Cough and low grade wheezing Continuous albeit low grade 
symptoms of asthma between between acute exacerbations often cough and wheezing almost 
exacerbati ons. presen t. always present. 
Degree of exercise Good exerc ise tolerance but may Exercise tolerance diminished. Very poor exercise tolerance 
tolerance not tolerate vigorous exercise , with marked limitation of 
0 
especia ll y prolo nged ru nnin g. ac ti vity. 
w 
Frequency of 1-2 times per month maxi mum 2-3 ti mes per week Considerable , almost ni ghtl y 
nocturnal asthma sleep inte rrupti on due to asthma. 
Chest ti ght in earl y morn ing. 
School or work Good school or work attendance School or work attendance may be Poor school or work attendance. 
attendance affected 
0 
""" 
Table 1 (continued) NIH guidelines (1991) criteria for classification of a sthma by severity of disease 
Characteri stics Mild Moderate Severe 
Pulmonary function 
a) Peak expi ratory PEFR>80% predicted . PEFR 60-80% predicted PEFR <60% predicted 
n ow rate (PEFR) Variability* <20% Vari ability20-30% Variabil ity>30% 
b) Spiro metry Minimal or no ev idence of Si gns of a irway o bstructi on on Substanti al degree of a irway o bstructi on 
a irway obstructi on on spi rometry a re ev ident. Flow on spirometry. Flow volu me curve 
spirometry. Normal expirato ry volu me c urve shows red uced shows marked concav it y. Spi romct ry 
flow volume curve; lung ex piratory n ow at low lung may not be norm ali zed even with hi gh 
volumes not increased. volu mes. Lung volumes often dose stero ids. May have substant ia l 
Usuall y a > 15% response to increased. Usua ll y a > 15% increase in lung volumes and ma rked 
acute ae rosol bronchod il ato r respo nse to acute aerosol unevenness of ventil ati on. Incomplete 
administration, even though bronchod il ator ad mini stra tion. reversibility to ac ute aerosol 
baseline near normal. bronchodil ator adm ini stration 
c)Methacholine Methacholine PC20>20mg/ml Methacholine PC202- Meth ac ho line PC20 <2mg/ml 
sensiti vi ty 20mg/ml 
*Vari ability: the difference between a mornin g and evenin g measure or a iiiong n1ornin g measurement s each clay fo r a week. 
0 
U'I 
Table 1 (continued) NIH guidelines (1991 ) criteria for classification of asthma by severity of disease 
Characteristics Mild Moderate Severe 
B. After optimal 
thernpyis 
established 
Response to and Response to bronchodilators in Periodic use of bronchodilators Requires continuous around the 
duration of therapy 12-24 hours, regu lar drug required during exacerbations fro a clock drug therapy including 
therapy is not usuall y required week or more. Systemic steroids daily cort icosteroids, either 
except for short periods of time. also usually required for aerosol or systemic, often in high 
exacerbations. Con tinuo us a round doses. 
the clock dru g therapy required. 
Regular use of anti-innarnmatory 
agents may be required for 
prolonged periods of time. 
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APPENDIX B DETAILS OF THE METHODS 
Data source and study population 
The data analyzed were from a sample of children (aged 2 to 19 years) treated for asthma 
during 1994 by the Medicaid program in Pennsylvania, USA. The data were collected 
during a medical care evaluation for the Department of Public Welfare of the 
Commonwealth of Pennsylvania. 
Medicaid is a program financing medical care for qualifying low-income patients. The 
eligibility fortreatment of children under a Medicaid program is influenced by the parents ' 
income and employment status. A substantial loss of patients due to changes in enrollment 
status have been reported in a 5 year period.' This study was restricted to children eligible 
for Medicaid enrollment as a minimum for 1994. This time frame is appropriate for 
studying the outcomes of treatment of childhood asthma because the study was evaluating 
medication effects which have a rapid onset of action and a reduction in acute asthma 
exacerbations could be expected to be observed in this time frame.' 
The data sources for the analyses were the primary care medical records and hospital and 
emergency department encounter files. Automated medication claims records were 
provided for comparison with the medical records of 106 patients. 
The data elements in Medicaid files that are required for claims payment are considered to 
have generally good accuracy.' However data that are not directly related to claims 
payment, may be of poorer quality and should be verified. This study included a check of 
the reliability of the primary care medical records as a source of information on asthma 
medications by comparing the agreement with medication claims. 
117 
Sample size and sampling strategy 
Each plan was requested to identify all Medicaid members who were diagnosed and treated 
for asthma during 1994 (International Classification of Diseases, Ninth Revision. Clinical 
modification code ICD-9=493) and select a random sample of 50 children (aged 2 to 19 
years in 1994) for study. 
The asthma diagnoses were confirmed by nurse reviewers checking the primary care 
medical records and therefore the study did not rely solely on the !CD 9 coding for the 
asthma diagnosis. Patients without a diagnosis of asthma in the medical records were not 
included in the study. 
The NIH guidelines include an algorithm for differential diagnosis of asthma and 
recommend a detailed medical history checking for key indicators for a possible diagnosis 
of asthma. physical assessment and then pulmonary function testing(spirometry) to 
establish the diagnosis.' Mild to moderate cases of asthma may be difficult to diagnose, 
especially among young children. The guidelines summarize differential diagnosis of 
asthma and indicate that wheezing by children due to asthma is often confused with 
wheezing due to recurrent respiratory infections. Reliance on the ICD-9 code alone without 
verification with the medical records would have been inappropriate for identification of a 
sample of asthmatic children. 
The age of the children I stJanuary 1994 was calculated from the date of birth. The age 
range of children included in the cohort was verified to be 2 to 19 years old. Children 
younger than 2 years old or over 19 years were excluded from the study. 
The plans provided 388 medical records and 347 were eligible after verifying the patient ' s 
age on I st January 1994 was between 2 to 19 years old ( 41 were less than 2 years old). 
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311 were eligible after confinning there was an asthma visit date with documentation of a 
prescription for an asthma medication during 1994 (36 out of 347 did not have 
documentation of a visit during 1994). 
Data collection 
A data collection instrument was created and abstracting instructions were provided to the 
nurse reviewers. The data collection was conducted on-site, with a separate data collection 
instrument for each patient. No data was collected directly from the physicians or patients. 
The data on asthma treatment provided by plan physicians between !st January 1993 and 
31st March 1995 were abstracted from the medical records. 
The nurse reviewers were asked to abstract data on the five most recent asthma related 
hospital admissions and emergency department visits from January 1993 through March 
1995. For each hospitalization or emergency department visit the nurse reviewer 
documented the admission dates, discharge dates and reason for visit or admission. The 
reasons listed on the data collection instrument included patients lack of compliance, wrong 
treatment plan, unusual exposure to tri gger, lack of guidance for medication late 
notification. other and not documented. 
For each primary care physician visit the nurse reviewer was asked to abstract from the 
medical record all the asthma related medications prescribed on each visit date between 
January 1993 through March 1995. Medication data abstracted from the medical records 
included details of the asthma medications prescribed (product name, route, directions, 
days supply), date prescribed and prescriber (primary care physician or other). 
The clinical data abstracted included date of birth, gender, date of initial asthma diagnosis, 
date of latest theophylline level , date of latest influenza vaccination. The data also included 
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the date of each physician visit (up to 10 visits), the types of patient education provided at 
each visit (abi lity to use peak flow meter, ability to use inhaler. how to use inhaled 
medications, side effects of medication, avoidance of triggers, action plan for 
exacerbations, use of diaries. and goals of treatment). For each visit there was a record of 
height, weight, blood pressure, a physical examination, medical history (symptoms and 
functional status), objective measures oflung function (peak expiratory flow rates, home 
use of a peak flow meter, spirometry results) and referrals to specialists (dates, type of 
specialist, reason). These were all recorded for each visit as·' yes·. ""no" or "not 
documented in the record". In addition the instrument allowed '·not applicable " to be 
recorded for ability to use peak flow meter, ability to use inhaler. how to use inhaled 
medications, or side effects of medications. 
The nurse used the information in the medical records and the NIH guidelines( 1991 )3 to 
classify the asthma severity at each primary care visit as mild, moderate or severe asthma. 
In the past the diagnosis criteria have varied for classifying asthma severity but the NIH 
guidelines include a working definition of mild, moderate and severe asthma severity. 
Access to the medical records allowed the NIH guidelines to be used to classify the children 
as mild , moderate or severe asthmatics at each physician visit when an asthma medication 
was prescribed. The analyses were then able to address confounding by asthma severity 
for example by stratified analyses and including a time dependent covariate for asthma 
severity in the Cox regression model. 
Medication claims from 4 managed care plans were also provided for a sample of I 06 of 
the children (aged 2 to 19 years) treated for asthma during 1994. The medication claims 
data included all the asthma medications dispensed (product name) and date dispensed. 
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The data recorded on the instrument were entered into a database and transferred with the 
automated medication claims records to the Department of Applied Pharrnaceutical Sciences 
at the University of Rhode Island. 
Data coding and screening 
The analyses were all perforrned using SAS 6.12. A SAS program was written to ensure 
that any duplicates of patient records were deleted. Missing values were changed to be 
represented by a single code for all the variables. Univariate descriptive statistics were 
examined using programs such as ' Proc Univariate'. A series of checks were made to 
ensure codes had been programmed appropriately. For age the range of the values, mean 
and standard deviations were checked to confirrn these were plausible. 
Asthma severity was coded as mild ( I), moderate (2) or severe (3) at each physician visit. 
The maximum asthma severity recorded during the study period was used to classify the 
children into mild, moderate and severe asthmatics. 
Asthma medications were coded as dichotomous variables :beta-agonists (oral or inhaled), 
preventive anti-inflammatory medications (i nhaled corticosteroids, inhaled cromolyn or 
nedocromil), oral theophylline or oral corticosteroids. The asthma medications were 
recorded by generic or Trade Names, so the coding of the asthma medication variables 
were carefully checked to ensure none of the medications had been missed and were 
recoded appropriately. Data on the route of administration was missing fortoo many 
patients to code oral or inhaled beta-agonists separately. 
The seasons were coded as a dichotomous variable for each physician visit. The fall to 
winter season was coded as 1st October to 31st March. 
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The dates for hospital admission and emergency department visits were used to determine 
whether the patients experienced these outcomes within the defined time period. Each 
variable was coded I for each patient experiencing an event or zero for those not having the 
event within the defined time period. 
The data for each patient was transposed to create a data set containing one record per 
patient. Each record contained the demographic information, plus asthma severity and 
medications for each primary care physician visit (maximum 10 visits). If the patient 
attended less than ten visits the data was coded as missing for the remaining visits. A SAS 
program was written to code the children as receiving undertreatment at each visit where the 
asthma severity was moderate or severe and no preventive medications were prescribed. 
For example; each record contained a unique patient identifier code, age, sex, hospital 
admission (0, I), emergency department visit (0, I), plus for each visit date asthma severity 
(coded 1.2,3), preventive medications {0, I), oral steroids (0, l ), undertreatment (0, l ) or 
season (0, l) etc. 
For all the analyses the data collected was censored for 31st December 1994. All the data 
collected before l st January 1993 or after 3 l st December 1994 were excluded from the 
analyses. For example, some hospital admissions were documented for patients for before 
I st January 1993 and these were excluded form the analyses. 
For the analyses using data for the period l stJanuary 1994 to 31st December 1994 the data 
before !st January were excluded from the data set. For the Cox regression analyses the 
beginning of person-time for an individual was defined as the date of the first physician 
visit when an asthma medication was prescribed between !st January 1993 and 31st 
December 1994. The end of person-time was defined as the first date for the outcome 
under evaluation after the first physician visit (either a hospital admission or an emergency 
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department visit for asthma or a course of oral steroids) orthe end of the study period (31 st 
December 1994). 
Prescribing anti-inflammatory medications in accordance with the NIH guidelines was 
determined by the following dichotomous variables: preventive medication (prescribed at 
least once) , preventive medication prescribed at 50% or more of the visits when other 
asthma medications were prescribed, undertreatment (preventive medication was not 
prescribed at least once when the children visited the primary care physician with moderate 
or severe asthma) or undertreatment at 50% or more of the visits when other asthma 
medications were prescribed. 
Forche reliability assessment, the medication claims data selected included the medication 
data (using date dispensed) for between January to December 1994. The medical record 
and medication claims data sets were merged using a unique patient identifier code and any 
unmatched records were not included in the analyses. The medication claims data before 
the first physician visit were not included in the analyses. Dichotomous codes were created 
for oral steroids and preventive medications dispensed using the medication claims records. 
In order to have confidence in the reliability of the study results the drug exposure 
classification using medication claims data was compared with the primary care physician 
medical records, which were the main source of data for our study. Nondifferential 
misclassification of dichotomous variables may bias the risk estimates towards the null 
value.4 but if there is differential misclassification then the effects on relative risk estimates 
are unpredictable.5 
The kappa statistic is commonly published in papers to demonstrate the reliability of a 
method for dichotomous variables.• The agreement between the medical records and 
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claims forthe medication dispensed was evaluated by calculating the percent agreement and 
kappa statistic for two dichotomous medication exposure variables (oral steroid course and 
preventive medication). In addition differential misclassification of exposure status was 
evaluated by calculating the kappa statistics for each group of children divided up by 
outcome. 
Multivariate analyses 
The outcomes studied were too infrequent to be analyzed as continuous variables, very few 
patients had more than one event during the study. The outcomes were therefore coded as 
dichotomous events. Cox regression was therefore the multivariate methods selected for 
the analyses of the clinical outcomes. For the logistic regression analyses the data analyzed 
was collected during 1994. The Cox regression analyses were able to adjust for the 
person-time contributed to the data set and allowed all the data collected between January 
1993 and December 1994 to be included in the analyses. Both methods allowed the 
creation of models from a combination of independent variables which are continuous, 
categorical, or discrete. Unlike many of the multivariate methods assumptions of 
multivariate normality, linearity and homoscedasticity are not required for the predictors 
included in the models. 
The SAS procedure PROC PHREG was used for the Cox regression analyses,7 and PROC 
LOGISTIC was used for the logistic regression analyses. The analyses used PROC 
PHREG so that both fixed and time dependent covariates could be included in the models. 
The coding of data and programming was complex in order to organize the data 
appropriately for PROC PHREG. The programs were developed from studying examples 
provided in SAS users' guides. 8 9 10 
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The analyses included fixed covariates for preventive medications and preventive 
medications prescribed at the last visit before the event, so the proportional hazard 
assumption was checked. The assumption was examined graphically using PROC 
LIFEfEST by checking the plots of cumulative hazard (i.e. log negative log survival 
probability) against log survival time can be considered parallel for selected dichotomized 
covariates. 
The linearity of the association of continuous variables with each dependent variable 
studied were examined and the variables coded appropriately before the analyses were 
progressed, for example. age was dichotomized for some of the multivariate analyses. 
Many of the drugs for asthma can appear to increase risk of adverse outcomes because the 
patients for whom asthma medications are prescribed may have an increased risk of 
frequent and severe asthma exacerbations.'' Consequently to address confounding by 
asthma severity, the multivariate analyses selected the children attending with either 
moderate or severe asthma before the outcome, included a covariate for severity or for Cox 
regression included severity as a time dependent covariate. The logistic regression analyses 
were able to stratify the patients by the maximum asthma severity recorded during the 
study. This is in line with NIH guidelines which classify patients as mild. moderate or 
severe based on the history before the asthma is treated. 
The introduction of time dependent covariates allows the status of each individual to vary 
during the study and the Cox regression model no longer assumed the effect of the 
covariate was the same at all the time points, even when recorded at irregular intervals. The 
models were able to include time dependent covariates for asthma severity and preventive 
medications. The Cox regression analyses used both fixed covariates for age or gender 
and time dependent covariates. 
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APPENDIX C OVERVIEW OF MAJOR FINDINGS 
There were three major findings from this study of the impact of the NIH guidelines on the 
treatment of childhood asthma by primary care providers: 
I) primary care providers imple"*'1ted the NIH recommendations by prescribing inhaled 
anti-inflammatory medications at least once for 61.1 % of the chi ldren with moderate or 
severe asthma during 1994 
2) the NIH recommendations to provide patient education were not fully implemented by 
the primary care providers because only 41.8% of the children received any patient 
education during 1994 
3) prescribing preventive medications to children with moderate or severe asthma reduced 
the risk of being prescribed courses of oral steroids (HR 0.42. 95% Cl 0.19-0.95) , after 
adjusting for age and asthma severity. 
The results from this study demonstrate the potential impact of the NIH recommendations 
on the clinical outcomes of asthmatic children. There may be an opportunity to further 
improve the outcomes for asthmatic children by supporting physicians and pharmacists to 
more fully implement the NlH recommendations for all the children with moderate or 
severe asthma. 
NIH guidelines recommend treatment of moderate or severe childhood asthma with 
preventive anti-inflammatory medication (inhaled corticosteroids, cromolyn or nedocromil) . 
The guidelines emphasize the importance of patient education about avoidance of triggers 
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and the management of asthma (written action plan for exacerbations. goals of treatment 
and how to use an inhaler). 
Children with moderate or severe asthma during 1994 were prescribed a beta-agonist 
(96%) and 61.1 % were prescribed preventive medications at least once. The NIH 
recommendations were not followed regularly because only 27.0% of the moderate or 
severe asthmatics were prescribed preventive medication more tban once during the year. 
In addition , providing patient education was only recorded for 41.8% of the children. 
The results suggested that the prescribing of preventive medications is related to sentinel 
clinical events and the NIH recommendations are not always routinely implemented for 
chi ldren with moderate or severe asthma. Logistic regression analyses indicated 
prescribing preventive medication was associated with moderate or severe compared to 
mild asthma (aOR 5.34, 95% CI 3.22-8.83) and age 5 to 19 years compared to 2 to 4 years 
(aOR 2. l l , 95% CI 1. 19-3.72). Prescribing preventive medication was also associated 
with a prior emergency department visit (aOR 2.27, 95% CI 1.244.16), after adjusting for 
age. 
Children younger than 5 years of age are recommended to be given courses of oral steroids 
for chronic severe asthma because they may be unable to use inhalers effectively. The NIH 
guidelines for the use of preventive medications were implemented on at least one occasion 
for 66.7% of the children aged 5 to I 9years old with moderate or severe asthma during 
1994. The prescribing was not therefore consistent with fully implementing the NIH 
guidelines for all the children attending with moderate or severe asthma; even after taking 
into account the difficulty of treating children under 5 years old with inhaled medications. 
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The NIH guidelines recommend anti-inflammatory medications but indicate that 
theophylline can be prescribed for childhood asthma. In this study the prescribing rates for 
theophylline were very low (4.8% ). and cannot therefore account for the apparent 
undertreatment of moderate or severe asthmatics with inhaled anti-inflammatory products. 
The low rates of repeat prescriptions for antinflammatory products amongst the children 
with moderate or severe asthma in our study cannot be fully explained by poor patient 
compliance with follow-up primary care visits. In our study, lack of continuity of care 
cannot completely explain the results because 38.9% of the children with moderate or 
severe asthma attended the primary care physician more than once and were not prescribed 
preventive medications. Low rates of repeat prescriptions for preventive medications were 
also obtained in other studies, although these included both adults and children. 1 ' 3 
Inadequate attendance for primary care physician follow up visits were shown by a study in 
asthmatic children in the Medicaid program in Massachusetts.< 
The reasons for not prescribing preventive medications to all the patients with moderate or 
severe asthma are not known in the current study. Under-treatment of asthmatic children 
has however also been recorded in three other studies which reported that at least 50% of 
the children were not prescribed preventive medication before either an admission to 
hospital or attending the emergency department. 5 6 7 
The NIH guidelines on the importance of on-going patient education and self-management 
of asthma do not appear to have been widely implemented by the primary care physicians 
during this study period. Patient education was documented for less than 50% of the 
children during 1994, regardless of the type of education. Action plans for severe 
exacerbations were the most frequent form of patient education provided and were given to 
the majority of severe asthmatics. Fewer than 25% of the children with moderate or severe 
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asthma were documented in the medical records as being provided information on the 
treatment goals or having the ability to use an inhaler correctly confirmed during 1994. No 
education on avoidance of environmental triggers was given to at least two thirds of the 
children with mild or moderate asthma and over a third of the children with severe asthma. 
In this study increasing asthma severity was associated with review of treatment goals. an 
action plan and the avoidance of triggers. There was no indication that children received 
additional patient education after either an emergency department visit or hospitalization . 
Prescribing preventive medication was associated with the provision of patient education 
(after adjusting for age and asthma severity), consequently children without preventive 
medication were also less likely to receive counseling. 
One limitation of our study was the use of medical records to evaluate patient education as 
the quality of the education routinely provided could not be assessed. The extent of the 
education provided may also have been underestimated; for example the ability to use an 
inhaler may be checked by pharmacists and not recorded in the medical records. In 
addition, education may be provided to the patient but not documented in the medical 
records by the health care provider. 
These results could be explained by differences between physicians or managed care plans 
in the extent to which NIH guidelines are implemented. The study design did not include a 
sample size large enough to allow comparisons between the different managed care plans or 
profile the prescribing practices of individual prescribers. For example, asthma specialists 
have been shown to be more likely to prescribe preventive medications than primary care 
physicians" 9 and access to or co-ordination of care by specialists 10 11 may have facilitated 
implementation of the NIH guidelines by some plans. 
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Prescribing preventive medication to children with moderate or severe asthma reduced the 
risk of being prescribed oral steroid courses. Cox regression analyses were conducted 
with time dependent covariates for being prescribed preventive medications and adjusting 
for asthma severity (mild, moderate or severe) , with a fixed covariate for age. Children 
diagnosed with moderate or severe asthma at least once who were prescribed preventive 
medication were less likely to require a course of oral steroids (Hazard Ratio 0.42 95% CI 
0.19-0.95) , after adjusting for age and asthma severity. No significant association was 
found using Cox regression between prescribing preventive medications and hospital 
admissions or an emergency department visits. 
Emergency department visits were shown in our Cox regression analyses to be consistently 
associated with prior severe asthma exacerbations or a course of oral steroids. The Cox 
regression models included asthma severity and preventive medications as time dependent 
covariates but could not also include oral steroids because of multicollinearity with asthma 
severity. A course of oral steroids is recommended by the NIH guidelines for the acute 
treatment of severe asthma exacerbations and therefore may have reduced the risk of 
adverse outcomes from undertreatment with inhaled anti-inflammatory medication. For 
example, one study showed starting or increasing steroid medications at the onset of a cold 
or flu reduced the odds of asthmatic children making an emergency department visit.5 
A disproportionate number of Medicaid children have been shown to rely on the emergency 
department instead of primary care providers for their asthma care12 and some parents 
prefer to use the emergency department. 13 '"' These patient and various health care system 
characteristics all pose challenges to Medicaid patients moving away from episodic 
attendance for crisis orientated, fragmented care for asthma exacerbations. 15 16 17 
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In our study emergency department visits were more common amongst 2 to 4 year olds. 
The NIH guidelines recognize this age group is less likely to be able to successfully co-
ordinate inhaling preventive medication. and may have to rel y instead on courses of oral 
steroids for acute exacerbations. The 0 to 4 year age group has been found to exhibit 
higher hospitali zation rates for asthma than other age groups 18 19 and there is evidence of 
children aged 2 to 4 years old making more emergency department visits.20 21 
One predisposing factor for emergency department visits or hospital admissions seems to 
be the season of the year as more events were recorded during fall or winter. Similar 
results have also been recorded in other studies and viral infections have been suggested as 
a possible explanation for these seasonal trends.22 23 In our study, it was not known 
whether a viral infection was considered the trigger for the asthma-related emergency 
department visit or hospital admission. Seasonal influences may explain why 
undertreatment at the last primary care physician visit before an emergency department visit 
or a course of oral steroids was associated in the Cox regression analyses with a 
significantly increased risk of both these adverse outcomes. The Cox regression analyses 
also included a time dependent covariate for season but the small sample size and low event 
rates may have prevented the study detecting an association between preventive medications 
and hospitalization or emergency department visits. 
Only a few population based studies have been published on the effectiveness of anti-
inflammatory medications for the treatment of childhood asthma, many of which have 
focused on severe asthmatics. However, a case control study of Medicaid children 
showed prescribing corticosteroid therapy was associated with a significant reduction in the 
total health care costs (hospitalizations, physician visits, outpatient visits and the cost of 
medications).24 Similarly, two studies of asthmatic children demonstrated preventive 
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medications confer significant protection against exacerbations of asthma leading to 
hospitalization. 25 26 A cohort study of the relative risk of readmission to hospital by 
asthmatic patients (age 5-54years) showed that using inhaled steroids reduced the risk of 
readmission during the period 16 days to 6 months after the first admission" or of fatal or 
near fatal asthma.28 Other studies have not however always demonstrated a protective 
effect for severe asthmatics of steroids from readmission of children'" or patients age (5-45 
years) 30 to hospitals. 
The information about prescribing medications was collected from the medical records 
rather than a separate medication claims database, consequently not all the prescriptions 
may have been actually dispensed or administered regularly as directed. Patient compliance 
is important for preventive medications to be beneficial and for children it may be especially 
complex as parents, school nurses and other carers may have to administer the medication. 
Many studies have identified poor compliance with preventive medication amongst 
preschoo131 and school children.32 Patient compliance was not measured in this study, 
therefore these data may underestimate the value of prescribing preventive medication to 
these children. 
The information collected from this Medicaid asthmatic population may not be generalizable 
to other children.33 The Medicaid eligibility criteria for this study means all the children 
were from poor families. It was not possible to compare the results from this Medicaid 
group with other patients attending these plans. In the present study medications were free 
for the patients; thus there was no cost incentive for patients to avoid having prescriptions 
dispensed for preventive medications. 
The managed care plans guarantee access for these Medicaid patients but there are many 
differences between poor minority families and health care providers that may influence 
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prescribing practices for example language. cultural barriers. or literacy levels.34 Indoor 
allergens, such as cockroaches, dust mites. pets or cigarette smoke are now recognized as 
important triggers for asthma, which may be particularly difficult for Medicaid eligible 
children to avoid.35 36 
The low socioeconomic status of these children means they might be unable to avoid some 
environmental triggers, have a higher frequency of severe asthma,37 38 and experience a 
lack of continuity of care more than insured children 15 16 17or under-use preventive services 
for asthma.39 4 The effectiveness of prescribing in accordance with the NIH guidelines was 
still however, clearly demonstrated as preventive medication significantly reduced. and 
undertreatment of moderate or severe asthma significantly increased the risk of prescribing 
a course of oral steroids. Reducing the asthma exacerbations requiring oral steroids would 
be expected to improve the quality of life for the children. 
This population-based study supports the effectiveness of prescribing inhaled preventive 
anti-inflammatory medication under conditions of actual use by a Medicaid population. 
This study shows that primary care physicians can improve the control of asthma by 
implementing the NIH guidelines and regularly prescribing anti-inflammatory medication 
for moderate or severe asthma. Our results also showed there was limited implementation 
of the NIH recommendations for prescribing preventive medication and providing patient 
education, which may have reduced the impact of the guidelines on improving the 
management of childhood asthma. This study supports the need for interventions to 
increase implementation of the NIH guidelines by primary care physicians and improve the 
treatment of childhood asthma. 
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